eMERGE-3 Depression Phenotype Pseudo Code

**Primary site: Kaiser Permanente Washington & University of Washington**

**Primary site contacts:  
Aaron Scrol (aaron.scrol@kp.org)  
Arvind Ramaprasan (Arvind.ramaprasan@kp.org)  
David Carrell (david.s.carrell@kp.org)**

**Version: April 17, 2019**

Contents

[Background & significance 3](#_Toc6380688)

[Measurement approach 3](#_Toc6380689)

[Granular longitudinal data 4](#_Toc6380690)

[Strategy for implementing this phenotype 4](#_Toc6380691)

[Depression types 4](#_Toc6380692)

[What to do about bipolar disorder? 4](#_Toc6380693)

[The “2/30/180” rule 5](#_Toc6380694)

[Exclusion criteria 5](#_Toc6380695)

[Phenotype logic and flow diagram 5](#_Toc6380696)

[Narrative summary of phenotype logic 7](#_Toc6380697)

[Depression diagnosis codes 8](#_Toc6380698)

[Depression diagnosis code granular data 8](#_Toc6380699)

[Table DEP-2. Format of de-identified, granular longitudinal depression diagnosis code data to be provided for each patient over for all available time periods. 8](#_Toc6380700)

[Antidepressant medications 9](#_Toc6380701)

[Table MED-2. Format of de-identified, granular longitudinal antidepressant medication data to be provided for each patient over for all available time periods. 9](#_Toc6380702)

[Antidepressant medications granular data 10](#_Toc6380703)

[Patient-reported depression scale (PRDS) scores 10](#_Toc6380704)

[Patient-reported depression scale (PRDS) score granular data 10](#_Toc6380705)

[Table PRDS. Format of de-identified, granular longitudinal depression patient reported depression scale (PRDS) data to be provided for each patient over for all available time periods. 11](#_Toc6380706)

[Depression psychotherapy 11](#_Toc6380707)

[Depression psychotherapy granular data 12](#_Toc6380708)

[Table PSY-2. Format of de-identified, granular longitudinal depression psychotherapy encounter data to be provided for each patient over for all available time periods. 12](#_Toc6380709)

[Electroconvulsive therapy 12](#_Toc6380710)

[Measured covariates (patient-level measures) 13](#_Toc6380711)

[Chart validation guidelines (primary and secondary sites) 15](#_Toc6380712)

[Table DEP. Depression diagnosis codes (ICD-9 and ICD10) grouped into three categories for identifying cases, and a fourth category used to disqualify patients from the control group.1 17](#_Toc6380713)

[Table BPD. ICD-9 and ICD-10 diagnosis codes used to identify patients with bipolar/manic disorder according to the “2/30/180” rule.1 19](#_Toc6380714)

[Table MED. Generic and brand names of antidepressant medications used to identify treatment for depression.1 22](#_Toc6380715)

[Table ECT. Electroconvulsive therapy procedure codes (updated 4/17/2019).1 24](#_Toc6380716)

[Table PSY. Procedure codes for delivery of psychotherapy. 25](#_Toc6380717)

[Table ANX. Anxiety diagnosis codes.1 27](#_Toc6380718)

[Table SCH. Schizophrenia and other psychotic (excluding bipolar) disorder diagnosis codes.1 30](#_Toc6380719)

[Table SEZ. Seizure diagnosis codes. 33](#_Toc6380720)

[Table SUD. Substance use disorder diagnoses.1 34](#_Toc6380721)

[Table SUI. Suicide or self harm diagnoses.1 51](#_Toc6380722)

[Table TOB. Tobacco use disorder and realated diagnosis codes. 58](#_Toc6380723)

[Table APM. Antipsychotic medication names.1 59](#_Toc6380724)

## Background & significance

Depression accounts for substantial morbidity and mortality worldwide and risk of experiencing it may have a genetic component. Depressive disorders manifest along a gradient from mild to severe.1 Electronic health record (EHR) data linked to large, multi-site biobanks2 facilitate exploration of the genetic component of depression.

## Measurement approach

Our measurement approach for this phenotype was designed to accommodate considerable variability across eMERGE study sites with respect to:

1. overall duration of patient enrollment in the health system,
2. frequency of health system encounters,
3. availability of information from which diagnoses may be inferred,
4. diagnostic coding practices, and
5. treatment modalities.

Our phenotype implementation therefore requests data for all eMERGE subjects from each participating site, and will postpone final determinations of case and control status until the requested data have been analyzed by the primary study site (KPWA/UW). Requested data includes typical covariate measures, but also includes granular, longitudinal data on each subject from key areas: diagnoses, medications, patient-reported depression scale measures, and psychotherapy (these data are described further below). The phenotype algorithm described in this pseudo code document will, *preliminarily*, classify each subject from a study site into one of four mutually exclusive categories:

1. likely cases,
2. likely controls,
3. potential cases, or
4. potential controls.

Based on further analysis of granular longitudinal data provided for each subject, some patients may be re-classified from a “potential” to a “likely” category, or excluded entirely from the analysis. For example, if preliminary classifications yield an ample number of likely major depression cases, and the data analyses show that 90% of these likely cases have >6 diagnoses (rather than just 2) distributed over a period of two or more years (rather than 30-180 days), we may adopt a more stringent case definition in the interest of reducing the chance of having false positives in the case group at the modest expsense of losing 10% of cases by the preliminary definition (i.e., the 2/30/180 rule). Similarly, if there are subjects classified initially as “likely controls” who have long histories of un-ambiguous antidepressant treatment . It is also possible that a potential case could be reclassified as a likely case if that subject’s data indicates substantial, sustained evidence of major depression based on patient reported depression scale scores—even if that subject’s pattern of depression diagnoses fails to meet our preliminary minimum criteria for classification as a likely case.

## Granular longitudinal data

As noted above, sites will provide granular, longitudinal data for each eMERGE subject. These data will be provided in addition to traditional covariate data (also described further below). Four types of granular data will be provided:

* depression diagnoses,
* antidepressant medications,
* patient-reported depression scale measures, and
* psychotherapy

Specifications for these four types of data are provided in the form of individual data dictionaries on PheKB. The data collected assure that the information needed to refine operationalization of the phenotype is made available, while avoiding collection of data that would threaten patient privacy or present a re-identification risk. In particular, no dates associated with longitudinal data will be collected. Instead, longitudinal data will be represented by a sequence number (1, 2, 3, … n) representing the first, second, third (and so on) time an event occurred while a subject was a given age (in integer years). No actual calendar dates or birth dates are collected. This will allow the primary study site to assess, for example, the gross frequency and duration of a particular form of evidence without having any information as to when it actually occurred. Patient ages will be identified by decade of birth, preventing reverse engineering of actual calendar dates associated with the collected longitudinal data.

## Strategy for implementing this phenotype

All data and logic needed to implement this phenotype algorithm can be derived from the granular longitudinal data described above. We therefore recommend as an implementation strategy that each site first prepare the granular longitudinal data, and then use it to execute the phenotype logic.

## Depression types

To identify depression cases, we will use International Classification of Disease Ninth (ICD-9) and Tenth (ICD-10) Revision diagnosis codes for depression listed in Table DEP, adapted from work published by others.3 We group depression diagnoses into the three categories based entirely on patterns of diagnoses:

1. depression with psychosis,
2. major depressive disorder, and
3. non-major depressive disorder.

As indicated by the logic in Figure 1, patients qualifying for more than one type of depression are assign the most severe type, where depression with psychosis (type 1) is considered the most severe and non-major depressive disorder (type 3) is considered the least severe.

## What to do about bipolar disorder?

Bipolar disorder may sometimes be misdiagnosed as major depression. Patients with bipolar disorder are not suitable as cases or controls *in primary analyses* for this phenotype (though they may be included in some secondary analyses). We will therefore identify and flag patients with evidence of bipolar disorder, but will not exclude such patients from data sets. Diagnosis codes used to identify patients with bipolar disorder were adopted from Castro et al.4 and are listed in Table BPD.

## The “2/30/180” rule

We use a “2/30/180” rule to assess most types of evidence for this phenotype. This rule requires evidence to be present on at least two (2) distinct calendar days that are at least thirty (30) days apart and not more than one hundred and eighty (180) days apart. For example, to qualify as a manor depression case (depression type 2), a patient’s record must have at least two instances of diagnosis codes for major depression, and the dates associated with these diagnoses must be at least 30 days but not more than 180 days apart. The 2/30/180 rule is intended to avoid interpreting as evidence of diagnosed depression “rule out” codes that only appear in a patient’s record once or for a brief period of time (i.e., <30 days), thereby suggesting the diagnosis code(s) were administrative artifacts of a diagnostic process that resulted in the subject not being diagnosed with depression. An assumption is that patients who actually have a particular diagnosis or receive a particular type of medication will have recurring evidence persisting for at least 30 days.

The 180-day feature of this rule is intended to acknowledge “rule-out” coding may appear more than once in a patient’s medical record. We assume that isolated recording of depression diagnoses separated by substantial periods of time (i.e., >180 days) most likely reflect multiple rule-out episodes of care, none of which result in a diagnosis of depression.

## Exclusion criteria


There are no exclusion criteria for this phenotype. Participating sites will provide data for all patients in their respective eMERGE biobanks.

## Phenotype logic and flow diagram

All patients from an eMERGE study site’s eMERGE biobank will be included in this phenotype. Data assembled for each patient will be used to identify likely cases, likely controls, potential cases, or potential controls. As noted above, the primary study site will analyze data provided by each study site to determine whether it is scientifically advantageous to alter definitions of cases and controls for final analyses.

The logic for classifying subjects into any of the four case/control categories is illustrated in Figure 1. The three types of depression are defined by diagnosis codes listed in Table DEP. Table DEP lists diagnoses codes grouped into three mutually exclusive categories, each category corresponding to one of the three depression types (type 1, type 2, or type 3 in Figure 1). A fourth category of codes in Table DEP is used to disqualify patients from the control group (per rules elaborated below).

The 2/30/180 rule for identifying depression cases is to be applied to codes within a single category in Table DEP. Thus, if on day X a patient has any diagnosis code for major depression, and 45 days later (day X+45) the same patient has any other of the diagnosis codes for major depression in Table DEP, that patient qualifies for major depression by the 2/30/180 rule. As noted above, depression cases may



qualify for two or more of the three depression types. When this occurs, the subject will be assigned to the most severe type as noted above.

Controls must not qualify for any of the depression categories, and must additionally not have any of the diagnoses in Table DEP section 4 (Depression diagnoses that exclude patients from qualifying as controls).

As noted above, we use the diagnoses for bipolar disorder listed in Table BPD to flag patients with bipolar disorder and exclude them from primary analyses.

## Narrative summary of phenotype logic

The following is a narrative summary of the depression phenotype logic summarized in Figure 1 above.

1. Bipolar disorder flag
   1. Qualifies by the 2/30/180 rule for diagnosis of bipolar disorder  
      (Note: this does not exclude a subject from the data set)
2. Case: depression with psychosis (type 1)
   1. Has any instances (ever) of any diagnosis code for depression, and
   2. Qualifies by the 2/30/180 rule for diagnosis of depression with psychosis
3. Case: major depression (type 2)
   1. Has any instances (ever) of any diagnosis code for depression, and
   2. Fails to qualify by the 2/30/180 rule for diagnosis of depression with psychosis, and
   3. Qualifies by the 2/30/180 rule for diagnosis of major depression
4. Case: non-major depression (type 3)
   1. Has any instances (ever) of any diagnosis code for depression, and
   2. Fails to qualify by the 2/30/180 rule for diagnosis of depression with psychosis, and
   3. Fails to qualify by the 2/30/180 rule for diagnosis of major depression, and
   4. Qualifies by the 2/30/180 rule for diagnosis of non-major depression

NOTE: Individuals who fail to qualify in any of the above cases should follow the phenotype logic illustrated in the lower half of the waterfall. For example, in Figure 1, 4263+1518 = 5781 individuals were reviewed if they qualified by the 2/30/180 rule for abnormal PRDS scores.

1. Control
   1. No instances (ever) of any diagnosis code for depression, and
   2. Fails to qualify by the 2/30/180 rule for abnormal PRDS scores, and
   3. Fails to qualify by the 2/30/180 rule for electroconvulsive therapy, and
   4. Fails to qualify by the 2/30/180 rule for antidepressant medications, and
   5. Fails to qualify by the 2/30/180 rule for depression psychotherapy
2. Potential control
   1. Has any instances (ever) of any diagnosis code for depression, and
   2. Fails to qualify by the 2/30/180 rule for diagnosis of depression with psychosis, and
   3. Fails to qualify by the 2/30/180 rule for diagnosis of major depression, and
   4. Fails to qualify by the 2/30/180 rule for diagnosis of non-major depression, and
   5. Fails to qualify by the 2/30/180 rule for abnormal PRDS scores, and
   6. Fails to qualify by the 2/30/180 rule for electroconvulsive therapy, and
   7. Fails to qualify by the 2/30/180 rule for antidepressant medications, and
   8. Fails to qualify by the 2/30/180 rule for depression psychotherapy
3. Potential case
   1. All other subjects qualify as potential cases

Code lists required to implement the above logic are found in Tables BPD, DEP, MED, PSY and ECT (below).

## Depression diagnosis codes

All depression-related diagnosis codes needed to implement this algorithm are listed in Table DEP. Codes are grouped into four categories—one category for each of the three depression case types, and a fourth category of codes that are used exclusively in the definition of controls.

### Depression diagnosis code granular data

Granular, longitudinal diagnosis data will be provided by a separate data table as specified in data dictionary DEP\_DEP\_DX\_Granular.CSV and described in Table DEP-2. To prepare these data we suggest the following steps:

* De-duplicate the data on EMERGEID, calendar date, and diagnosis code
* Calculate each patient’s age in integer years for each calendar date with a diagnosis code
* Sort the data by EMERGEID, age in integer years, calendar date, and diagnosis code
* Generate sequence numbers (1, 2, 3, …, n) for each record having the same patient age value
* Delete calendar date.
* Include all available diagnosis data (i.e., do not limit the data to diagnoses following the time point at which a patient first met the 2/30/180 rule)

De-identification is achieved by only recording the *sequential order* of diagnosis codes within each patient’s age in (integer) years.

| Table DEP-2. Format of de-identified, granular longitudinal depression diagnosis code data to be provided for each patient over for all available time periods. | | |
| --- | --- | --- |
| **Measure name** | **Measure description** | **Data type** |
| EMERGEID\* | Unique patient identifier in the eMERGE Network | Integer |
| PT\_AGE\_YEARS\* | Patient age in integer years when diagnosis code was recorded | Integer |
| DEP\_SEQ\_NO\_IN\_AGE\_YR\* | Sequence number (1, 2, 3, . . ., N) of chronological order of DEP\_DX\_CODE within PT\_AGE\_YEARS | Integer |
| DEP\_DX\_ICD\_ERA | ICD era of DEP\_DX\_CODE (9 or 10) | Integer |
| DEP\_DX\_CODE | Depression diagnosis code (de-duplicated by EMERGEID, PT\_AGE\_YEAR, and DEP\_SEQ\_NO\_IN\_AGE\_YR) | String, encoded value |
| \* Is a component of the primary key for this table (unique combinations of these measures are unique observations). | | |

## Antidepressant medications

The anti-depressant medications listed in Table MED will be used to identify anti-depressant medication treatment of depression. We assume these medications are used to treat depression when dispensed within 30 days of a qualifying ICD depression diagnosis code (Table DEP, depression types 1-3). To simplify implementation of this logic, a diagnosis code associated with any of the three types of depression appearing within +/-30 days of the medication dispense date is considered sufficient to qualify the dispensing as an antidepressant medication dispensing.

To identify these medications is your local site’s data we recommend that you use your preferred method typically employed by our site for identifying relevant medications. If you do not have a preferred method we recommend the following method:

1. Search for each generic medication name listed in Table MED in your pharmacy data’s generic medication field, then assemble a list of unique generic names returned.
2. Search for each brand name of medication names listed in Table MED in your pharmacy data’s brand name field, then assemble a list of unique brand names returned.
3. Locally review the two lists of medication names returned above, retaining all generic and brand names corresponding to the list in Table MED, and omitting any spurious matches. Spurious matches may occur when a non-antidepressant medication name contains within it a (shorter) antidepressant medication name.
4. After omitting spurious matches in the above step, consider all of the remaining medications names, generic and brand names, to be valid antidepressant medications.

| Table MED-2. Format of de-identified, granular longitudinal antidepressant medication data to be provided for each patient over for all available time periods. | | |
| --- | --- | --- |
| **Measure name** | **Measure description** | **Data type** |
| EMERGEID\* | Unique patient identifier in the eMERGE Network | Integer |
| PT\_AGE\_YEARS\* | Patient age in integer years when MED\_NAME was dispensed | Integer |
| MED\_SEQ\_NO\_IN\_AGE\_YR\* | Sequence number (1, 2, 3, . . ., N) of chronological order of MED\_NAME dispensing within PT\_AGE\_YEARS | Integer |
| MED\_NAME | Generic or bran name of antidepressant medication (de-duplicated by EMERGEID, PT\_AGE\_YEAR, and MED\_SEQ\_NO\_IN\_AGE\_YR) | String |
| MED\_DAYS\_DEP\_DX\_MIN | Minimum number of days from the medication dispensing date to the date of a depression diagnosis that falls within 30 days of the dispensing (value range: 0-30 or missing) | Integer |
| \* This variable is a component of the primary key for this table (unique combinations of these measures correspond to unique observations). | | |

### Antidepressant medications granular data

Granular, longitudinal antidepressant medication data will be provided by a separate data table as specified in data dictionary DEP\_MED\_Granular.CSV and described in Table MED-2. To achieve de-identification, we only record the *sequential order* of medication dispensings each patient within the patient’s age in (integer) years. Include all available antidepressant medication data (e.g., do not limit the data to the time period after which a patient qualified as a case).

## Patient-reported depression scale (PRDS) scores

When available as structured EHR data, patient-reported depression scale (PRDS) scores will be used in determining case/control status. The nine-item personal health questionnaire (PHQ-9) scale is an example of a PRDS commonly used in outpatient settings to assess the presence and severity of a patient’s depression. The PHQ-9 yields a score ranging from 0-27. As noted, we interpret scores ≥15 to be evidence of major depression, and scores in the range 10-14 to e evidence of non-major depression.

Other validated PRDS scores may also be used for this phenotype. **Please contact the people listed on the title page of this document if you would like to discuss PRDS data other than the PHQ-9 that is available as structured data at your site**. We will work with you to establish comparable maximum normal scores for any such PRDS scales to be used in this phenotype algorithm.

### Patient-reported depression scale (PRDS) score granular data

All available structured depression scale score data from all available encounters (ever) will be provided for each patient in the de-identified format described in Table PRDS and data dictionary DEP\_PRDS\_Granular.CSV. To achieve de-identification, we only record the sequential order of PRDS scale scores for each patient within the patient’s age in (integer) years. Include all available depression scale scores (e.g., do not limit the data to the time period after which a patient qualified as a case).

So that we may better interpret the values of PRDS scores provided in this table, the table includes a measure for documenting the maximum normal score associated with each PRDS record in the table. The maximum normal score is the “highest” value of the scale not considered to indicate *major depression*. Since different scales may have different ranges and maximum normal values, you will need to provide the maxum normal score for each *type* of PRDS score reprepresented in your study site’s data, and use them to populate measure PRDS\_MAX\_NORMAL. For example, on the PHQ-9 depression scale, which ranges form 0 to 27, scores ≥15 are considered to indicate “major depression;” the maxium normal score for a PHQ-9 PRDS score will therefore be 14, and and measure PRDS\_MAX\_NORMAL will be set equal to 14 for *all records* in this table reporting PHQ-9 scores.

| Table PRDS. Format of de-identified, granular longitudinal depression patient reported depression scale (PRDS) data to be provided for each patient over for all available time periods. | | |
| --- | --- | --- |
| **Measure name** | **Measure description** | **Data type** |
| EMERGEID\* | Unique patient identifier in the eMERGE Network | Integer |
| PT\_AGE\_YEARS\* | Patient age in integer years when PRDS\_SCORE was collected | Integer |
| PRDS\_SEQ\_NO\_IN\_AGE\_YR\* | Sequence number (1, 2, 3, . . ., N) of chronological order of PRDS\_SCORE within PT\_AGE\_YEARS | Integer |
| PRDS\_SCORE\_NAME | Name of the depression scale measured by SCALE\_SCORE | String |
| PRDS\_SCORE | Score from the scale indicated by SCALE\_SCORE\_NAME | Integer |
| PRDS\_MAX\_NORMAL | Maximum value of SCALE\_SCORE considered normal (or not indicative of *major* depression) for SCALE\_SCORE\_NAME | Integer |
| \* This variable is a component of the primary key for this table (unique combinations of these measures correspond to unique observations). | | |

## Depression psychotherapy

Depression psychotherapy is a form of evidence that a patient may have clinically diagnosed depression. We will consider as evidence of depression psychotherapy structured data of two types: 1) records of outpatient encounters *accompanied within 30 days (before or after) of a diagnosis of depression*, 2) records of inpatient encounters with an admission diagnosis or discharge diagnosis of depression, and 3) delivery of psychotherapy documented by standard procedure codes.

The operational definition of **outpatient psychotherapy encounters**, which will likely need to be tailored to reflect site-specific naming conventions and practices, will include regular-duration face-to-face encounters with healthcare professionals qualified to deliver psychotherapy. At the primary phenotype development site (KPWA/UW) such encounters occur through clinical departments named “Behavioral Health,” “Mental Health,” or “Psychiatry;” and qualifying providers include MDs, Social Workers, and Masters-trained clinical psychologists. Any of the three types of depression diagnoses listed in Table DEP (types 1, 2, or 3) occurring within 30 days of the outpatient encounter (before, on or after the encounter date) will qualify the encounter as psychotherapy (i.e., the accompanying diagnosis code does not have to be of the same type as the patient’s designated depression type).

**Inpatient psychotherapy** includes inpatient encounters where any of the associated admission and/or discharge diagnoses include depression of any of the three types listed in Table DEP.

**Psychotherapy documented by procedure coding** includes receipt by the patient of any of the procedures listed in Table PSY, below.

### Depression psychotherapy granular data

All available data documenting depression psychotherapy encounters (ever) will be provided for each patient in the de-identified format described in Table PSY-2 and data dictionary DEP\_PSY\_Granular.CSV. To achieve de-identification, we only record the sequential order of psychotherapy encounters for each patient within the patient’s age in (integer) years. Include all available psychotherapy data (e.g., do not limit the data to the time period after which a patient qualified as a case).

| Table PSY-2. Format of de-identified, granular longitudinal depression psychotherapy encounter data to be provided for each patient over for all available time periods. | | |
| --- | --- | --- |
| **Measure name** | **Measure description** | **Data type** |
| EMERGEID\* | Unique patient identifier in the eMERGE Network | Integer |
| PT\_AGE\_YEARS\* | Patient age in integer years when PSY\_THER\_ENC\_TYPE occurred | Integer |
| PSY\_SEQ\_NO\_IN\_AGE\_YR\* | Sequence number (1, 2, 3, . . ., N) of chronological order of PSY\_THER\_ENC\_TYPE within PT\_AGE\_YEARS | Integer |
| PSY\_THER\_ENC\_TYPE | Type of psychotherapy encounter (O=outpatient, I=inpatient, P=procedure-coded); only include encounter types O and I if accompanied in the EHR by a diagnosis code from Table DEP (types 1, 2, or 3) within +/- 30 days of the encounter date | String, encoded vaue |
| PSY\_DAYS\_DEP\_DX | Number of days before (negative values) or after (positive values) the date of PSY\_THER\_ENC\_TYPE when a diagnosis from Table DEP (types 1, 2, or 3) appeared; limit to diagnosis codes +/- 30 days from the encounter date; if multiple diagnoses were recorded within +/-30 days, report the code occurring the fewest number of days before or after the encounter date (for ties between a negative and a positive value report the negative value); PSY\_DAYS\_DEP\_DX may be missing if PSY\_THER\_ENC\_TYPE = P | Integer |
| \* This variable is a component of the primary key for this table (unique combinations of these measures correspond to unique observations). | | |

## Electroconvulsive therapy

electroconvulsive therapy is rare but strong evidence of major depressive disorder.6 Because it is so rare it is not necessary to collect granular data of these procedures. Instead, we will capture evidence of electroconvulsive therapy only in the patient-level covariate data (data dictionary DEP\_ECV\_Granular.CSV). The presence of any procedure code listed in **Table ECT** will be considered evidence of electroconvulsive therapy.

## Measured covariates (patient-level measures)

The following measures will be operationalized at the patient-level for each subject and provided as specified in data dictionary DEP\_Cov\_Pt\_Level\_YYYY\_MM\_DD.CSV (where YYYY\_MM\_DD for the first-released data dictionary is 2019\_01\_31), available on PheKB. Specifications for each measure are included in the data dictionary. These measures are:

1. Unique patient identifier (measure name: EMERGE\_ID)
2. Depression case type 1, depression with psychosis, status (1=Yes/0=No; measure name: CASE\_DEP\_W\_PSY\_YN)
3. Depression case type 2, major depression, status (1=Yes/0=No; measure name: CASE\_MAJ\_DEP\_YN)
4. Depression case type 3, non-major depression, status (1=Yes/0=No; measure name: CASE\_NON\_MAJ\_DEP\_YN)
5. Depression control status (1=Yes/0=No; measure name: DEP\_CONTROL\_STATUS\_YN)
6. Potential case status (1=Yes/0=No; measure name: POTENTIAL\_CASE\_STATUS\_YN)
7. Potential control status (1=Yes/0=No; measure name: POTENTIAL\_CONTROL\_STATUS\_YN)
8. Sex (measure name: SEX)
9. Race (measure name: RACE)
10. Ethnicity (measure name: ETHNICITY)
11. Diagnosis of bipolar disorder (per 2/30/180 rule applied to diagnosis codes in Table BPD), ever known, (1=Yes/0=No; measure name: BIPOLAR\_DISORDER\_YN)
12. Among patients with BIPOLAR\_DISORDER\_YN= 1 (Yes), age in years at the first instance of any code in Table BPD, even if it appears before the patient first qualified by the 2/30/180 rule (measure name: AGE\_BPD\_FIRST\_INST)
13. Among patients with BIPOLAR\_DISORDER\_YN= 1(Yes), age in years at last known nstance of any single bipolar disorder diagnosis code occurring on/after the date the patient satisfies the 2/30/180 rule (measure name: AGE\_BPD\_LAST\_INST)
14. Diagnosis of suicide attempt or self-harm using codes in Table SUI (where the occurrence of any single code is sufficient), ever known (1=Yes/0=No; measure name: SUICIDE\_SELF\_HARM\_YN)
15. Age in years at first known diagnosis code for suicide attempt or self-harm (measure name: AGE\_SUI\_FIRST\_INST)
16. Age in years at last known diagnosis code for suicide attempt or self-harm (measure name: AGE\_SUI\_LAST\_INST)
17. Among depression cases (i.e., patients with CASE\_DEP\_W\_PSY\_YN=1 (Yes) **or** CASE\_MAJ\_DEP\_YN=1 (Yes) **or** CASE\_NON\_MAJ\_DEP\_YN=1 (Yes)), age in years when the patient first qualified as a case (type 1, 2 or 3) by the corresponding 2/30/180 rule (measure name: AGE\_DEP\_DX\_2\_30\_180)
18. Age in years when patient first qualified by the 2/30/180 rule for having PRDS scores above the maximum normal score; applies to all patients regardless of case or control status (measure name: AGE\_PRDS\_QUAL\_2\_30\_180)
19. Age in years when patient first qualified by the 2/30/180 rule for having received antidepressant medication (using codes in Table MED); applies to all patients regardless of case or control status (measure name: AGE\_MED\_QUAL\_2\_30\_180)
20. Age in years when patient first qualified by the 2/30/180 rule for having received depression treatment by psychotherapy (using codes in Table PSY); applies to all patients regardless of case or control status (measure name: AGE\_PSY\_QUAL\_2\_30\_180)
21. Age in years at earliest known instance of depression treatment by electroconvulsive therapy (using codes in Table ECT whare any single instance of a code qualifies); applies to all patients regardless of case or control status (measure name: AGE\_ECT\_FIRST\_INST)
22. Eariliest BMI (earliest known measurement of weight in kilograms divided by height in meters squared; measure name: BMI\_EARLIEST)
23. BMI, earliest age; age in years at earliest ever measured BMI (measure name: AGE\_BMI\_EARLIEST)
24. Latest (most recent) BMI (most recently known measure of weight in kilograms divided by their height in meter squared; measure name: BMI\_LATEST)
25. BMI, most recent age; age in years at most recently measured BMI (measure name: AGE\_BMI\_LATEST)
26. Diagnosis of substance use disorder (per 2/30/180 rule), ever known, using codes in Table SUD (1=Yes/0=No; measure name: SUD\_DX\_YN)
27. Among patients with SUD\_DX\_YN = 1 or Yes, age in years at the first known diagnosis of substance use disorder (first instance of a single code, including codes appearing before the patient qualified by the 2/30/180 rule; measure name: AGE\_SUD\_FIRST\_INST)
28. Among patients with SUD\_DX\_YN = Yes, age in years at the last known diagnosis of substance use disorder (regardless of whether this last known code satisfies the 2/30/180 rule; measure name: AGE\_SUD\_LAST\_INST)
29. Diagnosis of tobacco use disorder (per 2/30/180 rule), ever known, using codes in Table TOB (1=Yes/0=No; measure name TUD\_YN)
30. Diagnosis of schizophrenia or other psychosis, excluding bipolar disorder, ever known, using codes in Table SCH and applying the 2/30/180 rule, (1=Yes/0=No; measure name = SCH\_YN)
31. Diagnosis of anxiety disorder (per 2/30/180 rule), ever known, using codes in Table ANX (1=Yes/0=No; measure name =ANXIETY\_YN)
32. Anti-psychotic medication exposure (per 2/30/180 rule applied to medications listed in Table APM), ever (1=Yes/0=No; measure name= APM\_YN).
33. Seizure diagnoses (per 2/30/180 rule), ever known, using codes in Table SEZ (1=Yes/0=No; measure name: SEIZURE\_YN)
34. Among patients with SEIZURE\_YN= 1 (Yes), age in years at the first known diagnosis of seizure (first instance of a single code, including codes appearing before the patient qualified by the 2/30/180 rule; measure name: AGE\_SEIZURE\_FIRST\_INST)
35. Among patients with SEIZURE\_YN = 1(Yes), age in years at the last known diagnosis of seizure (regardless of whether this last known code satisfies the 2/30/180 rule; measure name: AGE\_SEIZURE\_LAST\_INST)
36. Total count of distinct calendar days with PRDS scores available (derived from Table PRDS). (measure name: TOT\_CAL\_DAYS\_PRDS)
37. Total count of distinct calendar years with PRDS scores available (derived from Table PRDS). (measure name: TOT\_CAL\_YEARS\_PRDS)
38. Number of distinct calendar days with depression scores above PRDS\_DAYS\_ABOVE\_NORM (i.e., abnormal) calculated by comparing the values of PRDS\_SCORE and PRDS\_MAX\_NORMAL in granular data table DEP\_PRDS\_Granular.CSV; see Table PRDS (measure name: TOT\_CAL\_DAYS\_PRDS\_ABNORM)
39. Number of distinct calendar years with depression scores above PRDS\_MAX\_NORMAL (i.e., abnormal) calculated by comparing the values of PRDS\_SCORE and PRDS\_MAX\_NORMAL in granular data table DEP\_PRDS\_Granular.CSV; see Table PRDS; measure name: TOT\_CAL\_DAYS\_YEARS\_ABNORM)
40. Age in integer years at earliest healthcare system contact (measure name: AGE\_HS\_CONTACT\_FIRST)
41. Age in integer years at last healthcare system contact or death (measure name: AGE\_HS\_CONTACT\_LAST)
42. Total count of calendar years with any healthcare system contact (measure name: TOT\_CAL\_YEARS\_HS\_CONTACT)
43. Total count of calendar years with any medication dispensings (or medication orders, if only orders are known) by the health care system (measure name: TOT\_CAL\_YEARS\_RX)
44. Total count of calendar years with either healthcare system contact or medication dispensings (or medication orders, if only orders are known) by the health care system (measure name: TOT\_CAL\_YEARS\_HS OR\_RX)
45. Patient is known to be deceased (Yes/No) (measure name: DECEASED\_YN)

## Chart validation guidelines (primary and secondary sites)

Chart validation should be focused on the following two groups of study subjects:

1. Cases with major depression (case type 2)
2. Controls

Case type 1 (depression with psychosis) and case type 3 (non-major depression) are of less interest scientifically. The objectives of this study will therefore be best served by focusing validation efforts on case type 2 and controls.

**Procedure for reviewing charts**

The goal of this chart review is to determine if a clinician familiar with the patient’s care stated that the patient had a condition of interest (e.g., major depression), and recorded this somewhere in the patient’s chart. It is not necessary that DSM-5 criteria for depression are documented in the chart; a clinician’s documentation labeling the patient as having the condition is sufficient. It is not necessary for the clinical documentation to use the exact term “major depression;” however, the *meaning* of what is recorded in the chart must indicate the patient has been diagnosed with the condition (e.g., major depression).

Chart reviews may be performed by a clinician or other qualified person. Foe example, chart reviewers at KPWA are professional chart abstractors who consult as needed with a clinical domain expert (e.g., a clinician).

We recommend the following steps be used when reviewing individual charts. Note that it is not necessary to complete all of these steps if solid evidence the patient has the condition of interest is identified in the early steps.

1. Using the EHR’s built-in text search capability to search for and review chart notes containing the term “depression.” As needed, also search for terms beginning with the letters "depress" or terms used to document depression assessments, such as "PHQ".
2. Pay special attention to encounters with Behavioral Health, Mental Health or similar department designations.
3. When evidence of depression is found, confirm that at least some of the documentation is based on face-to-face encounters with the patient.
4. Also review all inpatient admission and discharge summaries containing the term “depression.”
5. Review all encounters that include documentation of Past Medical History, History and Physical, Well Adult Health Check, Health Maintenance Visit, Preventive Care Visits, Routine General Medical Exam, or similar for any evidence of depression that satisfies criteria specified in the algorithm pseudo code. Pay close attention to the medication review and review of chronic conditions. Also pay attention to care plans that may document depression.
6. If your institution performs a Wellness Questionnaire Review or similar review which specifically asks questions about depression, pay close attention to those reviews for evidence of clinician documented depression (if not in the review itself, then search for it elsewhere).
7. Review other incidental records, including scanned documents attached to the patient’s medical record, that could potentially include a diagnosis of depression, including encounters with external care providers, nursing home visits, home health visits, and hospice notes.
8. Pay special attention to the records of patients with diagnoses of a serious illnesses or major medical events (such as stroke, situational grief or stress, PTSD, Alcohol/Drug dependence/disorder) to distinguish transient conditions (which do not satisfy our definition of depression) from chronic conditions that constitute depression or major depression.
9. If there are EHR records from an external provider that are accessible from the patient’s chart (e.g., via Epic Care Everywhere functionality between two institutions that both use Epic), review any such records previously accessed by local practitioners (once accessed by a local practitioner, the link to the external record persists in our EHR).

| Table DEP. Depression diagnosis codes (ICD-9 and ICD10) grouped into three categories for identifying cases, and a fourth category used to disqualify patients from the control group.1 | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**2 | **ICD description** |
| **Type 1. Depression diagnoses for case type 1,depression with psychosis** | | | |
| 1 | 9 | 296.34 | Major depressive affective disorder, recurrent episode, severe, specified as with psychotic behavior |
| 2 | 9 | 298.0 | Depressive type psychosis |
| 3 | 10 | F32.3 | Major depressive disorder, single episode, severe with psychotic features |
| 4 | 10 | F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms |
| **Type 2. Depression diagnoses for case type 2, major depression** | | | |
| 5 | 9 | 296.20 | Major depressive affective disorder, single episode, unspecified |
| 6 | 9 | 296.21 | Major depressive affective disorder, single episode, mild |
| 7 | 9 | 296.22 | Major depressive affective disorder, single episode, moderate |
| 8 | 9 | 296.23 | Major depressive affective disorder, single episode, severe |
| 9 | 9 | 296.25 | Major depressive affective disorder, single episode, in partial or unspecified remission |
| 10 | 9 | 296.26 | Major depressive affective disorder, single episode, in full remission |
| 11 | 9 | 296.30 | Major depressive affective disorder, recurrent episode, unspecified |
| 12 | 9 | 296.31 | Major depressive affective disorder, recurrent episode, mild |
| 13 | 9 | 296.32 | Major depressive affective disorder, recurrent episode, moderate |
| 14 | 9 | 296.33 | Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior |
| 15 | 9 | 296.35 | Major depressive affective disorder, recurrent episode, in partial or unspecified remission |
| 16 | 9 | 296.36 | Major depressive affective disorder, recurrent episode, in full remission |
| 17 | 10 | F32.0 | Major depressive disorder, single episode, mild |
| 18 | 10 | F32.1 | Major depressive disorder, single episode, moderate |
| 19 | 10 | F32.2 | Major depressive disorder, single episode, severe without psychotic features |
| 20 | 10 | F32.4 | Major depressive disorder, single episode, in partial remission |
| 21 | 10 | F32.5 | Major depressive disorder, single episode, in full remission |
| 22 | 10 | F32.9 | Major depressive disorder, single episode, unspecified |
| 23 | 10 | F33.0 | Major depressive disorder, recurrent, mild |
| 24 | 10 | F33.1 | Major depressive disorder, recurrent, moderate |
| 25 | 10 | F33.2 | Major depressive disorder, recurrent severe without psychotic features |
| 26 | 10 | F33.40 | Major depressive disorder, recurrent, in remission, unspecified |
| 27 | 10 | F33.41 | Major depressive disorder, recurrent, in partial remission |
| 28 | 10 | F33.42 | Major depressive disorder, recurrent, in full remission |
| 29 | 10 | F33.9 | Major depressive disorder, recurrent, unspecified |
| **Type 3. Depression diagnoses for case type 3, non-major depression** | | | |
| 30 | 9 | 311 | Depressive disorder, not elsewhere classified |
| 31 | 9 | 300.4 | Dysthymic disorder |
| 32 | 9 | 309.1 | Prolonged depressive reaction |
| 33 | 10 | F32.89 | Other specified depressive episodes |
| 34 | 10 | F33.8 | Other recurrent depressive disorders |
| 35 | 10 | F43.21 | Adjustment disorder with depressed mood |
| **4. Depression diagnoses that exclude patients from qualifying as controls.**3 | | | |
| 36 | 9 | 296.24 | Major depressive affective disorder, single episode, severe, specified as with psychotic behavior |
| 37 | 9 | 296.82 | Atypical depressive disorder |
| 38 | 9 | 301.12 | Chronic depressive personality disorder |
| 39 | 9 | 301.13 | Cyclothymic disorder |
| 40 | 9 | 309.0 | Adjustment disorder with depression |
| 41 | 10 | F06.32 | Mood disorder due to known physiological condition with major depressive-like episode |
| 42 | 10 | F06.31 | Mood disorder due to known physiological condition with depressive features |
| 43 | 10 | F32.81 | Premenstrual dysphoric disorder |
| 44 | 10 | F34.0 | Persistent mood [affective] disorders: Cyclothymic disorder |
| 45 | 10 | F34.1 | Persistent mood [affective] disorders: Dysthymic disorder |
| 46 | 10 | F34.81 | Persistent mood [affective] disorders: Disruptive mood dysregulation disorder |
| 47 | 10 | F34.89 | Persistent mood [affective] disorders: Other specified persistent mood disorders |
| 48 | 10 | F34.9 | Persistent mood [affective] disorder, unspecified |
| 49 | 10 | F39 | Unspecified mood [affective] disorder |
| 50 | 10 | F43.23 | Adjustment disorder with mixed anxiety and depressed mood |
| 51 | 10 | F53 | Puerperal psychosis |
| 1. This code set was adapted from the list curated by the Mental Health Research Network (see GitHub).  2. Codes in a patient’s record must match the listed codes exactly; codes with additional characters or digits are not valid matches.  3. Code 309.28 was intentionally omitted from category 4. | | | |

| Table BPD. ICD-9 and ICD-10 diagnosis codes used to identify patients with bipolar/manic disorder according to the “2/30/180” rule.1 | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **Code2** | **Description** |
| 1 | 9 | 296.0 | Manic disorder, single episode |
| 2 | 9 | 296.00 | Bipolar I disorder, single manic episode |
| 3 | 9 | 296.01 | Manic disorder, single episode, mild degree |
| 4 | 9 | 296.02 | Manic disorder, single episode, moderate degree |
| 5 | 9 | 296.03 | Severe bipolar I disorder, single manic episode without psychotic features |
| 6 | 9 | 296.04 | Severe bipolar I disorder, single manic episode with psychotic features |
| 7 | 9 | 296.05 | Manic disorder, single episode, in partial or unspecified remission |
| 8 | 9 | 296.06 | Bipolar I disorder, single manic episode, in remission |
| 9 | 9 | 296.1 | Manic disorder, recurrent episode |
| 10 | 9 | 296.10 | Manic disorder, recurrent episode, unspecified degree |
| 11 | 9 | 296.11 | Manic disorder, recurrent episode, mild degree |
| 12 | 9 | 296.12 | Manic disorder, recurrent episode, moderate degree |
| 13 | 9 | 296.13 | Manic disorder, recurrent episode, severe degree, without mention of psychotic behavior |
| 14 | 9 | 296.14 | Manic disorder, recurrent episode, severe degree, specified as with psychotic behavior |
| 15 | 9 | 296.15 | Manic disorder, recurrent episode, in partial or unspecified remission |
| 16 | 9 | 296.16 | Manic disorder, recurrent episode, in full remission |
| 17 | 9 | 296.4 | Bipolar affective disorder, manic |
| 18 | 9 | 296.40 | Bipolar I disorder, most recent episode manic |
| 19 | 9 | 296.41 | Mild bipolar I disorder, most recent episode manic |
| 20 | 9 | 296.42 | Moderate bipolar I disorder, most recent episode manic |
| 21 | 9 | 296.43 | Severe manic bipolar I disorder without psychotic features |
| 22 | 9 | 296.44 | Bipolar affective disorder, manic, severe degree, specified as with psychotic behavior |
| 23 | 9 | 296.45 | Bipolar affective disorder, manic, in partial or unspecified remission |
| 24 | 9 | 296.46 | Bipolar affective disorder, manic, in full remission |
| 25 | 9 | 296.5 | Bipolar affective disorder, depressed |
| 26 | 9 | 296.50 | Bipolar affective disorder, depressed, unspecified degree |
| 27 | 9 | 296.51 | Bipolar affective disorder, depressed, mild degree |
| 28 | 9 | 296.52 | Bipolar affective disorder, depressed, moderate degree |
| 29 | 9 | 296.53 | Bipolar affective disorder, depressed, severe degree, without mention of psychotic behavior |
| 30 | 9 | 296.54 | Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior |
| 31 | 9 | 296.55 | Bipolar affective disorder, depressed, in partial or unspecified remission |
| 32 | 9 | 296.56 | Bipolar affective disorder, depressed, in full remission |
| 33 | 9 | 296.6 | Bipolar affective disorder, mixed |
| 34 | 9 | 296.60 | Bipolar affective disorder, mixed, unspecified degree |
| 35 | 9 | 296.61 | Bipolar affective disorder, mixed, mild degree |
| 36 | 9 | 296.62 | Bipolar affective disorder, mixed, moderate degree |
| 37 | 9 | 296.63 | Bipolar affective disorder, mixed, severe degree, without mention of psychotic behavior |
| 38 | 9 | 296.64 | Bipolar affective disorder, mixed, severe degree, specified as with psychotic behavior |
| 39 | 9 | 296.65 | Bipolar affective disorder, mixed, in partial or unspecified remission |
| 40 | 9 | 296.66 | Bipolar affective disorder, mixed, in full remission |
| 41 | 9 | 296.7 | Bipolar affective disorder, unspecified |
| 42 | 9 | 296.8 | Manic-depressive psychosis, other and unspecified |
| 43 | 9 | 296.80 | Manic-depressive psychosis, unspecified |
| 44 | 9 | 296.81 | Atypical manic disorder |
| 45 | 9 | 296.89 | Other manic-depressive psychosis |
| 46 | 10 | F30 | Manic episode |
| 47 | 10 | F30.1 | Manic episode without psychotic symptoms |
| 48 | 10 | F30.10 | Manic episode without psychotic symptoms, unspecified |
| 49 | 10 | F30.11 | Manic episode without psychotic symptoms, mild |
| 50 | 10 | F30.12 | Manic episode without psychotic symptoms, moderate |
| 51 | 10 | F30.13 | Manic episode, severe, without psychotic symptoms |
| 52 | 10 | F30.2 | Manic episode, severe with psychotic symptoms |
| 53 | 10 | F30.3 | Manic episode in partial remission |
| 54 | 10 | F30.4 | Manic episode in full remission |
| 55 | 10 | F30.8 | Other manic episodes |
| 56 | 10 | F30.9 | Manic episode, unspecified |
| 57 | 10 | F31 | Bipolar disorder |
| 58 | 10 | F31.0 | Bipolar disorder, current episode hypomanic |
| 59 | 10 | F31.1 | Bipolar disorder, current episode manic without psychotic features |
| 60 | 10 | F31.10 | Bipolar disorder, current episode manic without psychotic features, unspecified |
| 61 | 10 | F31.11 | Bipolar disorder, current episode manic without psychotic features, mild |
| 62 | 10 | F31.12 | Bipolar disorder, current episode manic without psychotic features, moderate |
| 63 | 10 | F31.13 | Bipolar disorder, current episode manic without psychotic features, severe |
| 64 | 10 | F31.2 | Bipolar disorder, current episode manic severe with psychotic features |
| 65 | 10 | F31.3 | Bipolar disorder, current episode depressed, mild or moderate severity |
| 66 | 10 | F31.30 | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified |
| 67 | 10 | F31.31 | Bipolar disorder, current episode depressed, mild |
| 68 | 10 | F31.32 | Bipolar disorder, current episode depressed, moderate |
| 69 | 10 | F31.4 | Bipolar disorder, current episode depressed, severe, without psychotic features |
| 70 | 10 | F31.5 | Bipolar disorder, current episode depressed, severe, with psychotic features |
| 71 | 10 | F31.6 | Bipolar disorder, current episode mixed |
| 72 | 10 | F31.60 | Bipolar disorder, current episode mixed, unspecified |
| 73 | 10 | F31.61 | Bipolar disorder, current episode mixed, mild |
| 74 | 10 | F31.62 | Bipolar disorder, current episode mixed, moderate |
| 75 | 10 | F31.63 | Bipolar disorder, current episode mixed, severe, without psychotic features |
| 76 | 10 | F31.64 | Bipolar disorder, current episode mixed, severe, with psychotic features |
| 77 | 10 | F31.7 | Bipolar disorder, currently in remission |
| 78 | 10 | F31.70 | Bipolar disorder, currently in remission, most recent episode unspecified |
| 79 | 10 | F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic |
| 80 | 10 | F31.72 | Bipolar disorder, in full remission, most recent episode hypomanic |
| 81 | 10 | F31.73 | Bipolar disorder, in partial remission, most recent episode manic |
| 82 | 10 | F31.74 | Bipolar disorder, in full remission, most recent episode manic |
| 83 | 10 | F31.75 | Bipolar disorder, in partial remission, most recent episode depressed |
| 84 | 10 | F31.76 | Bipolar disorder, in full remission, most recent episode depressed |
| 85 | 10 | F31.77 | Bipolar disorder, in partial remission, most recent episode mixed |
| 86 | 10 | F31.78 | Bipolar disorder, in full remission, most recent episode mixed |
| 87 | 10 | F31.8 | Other bipolar disorders |
| 88 | 10 | F31.81 | Bipolar ii disorder |
| 89 | 10 | F31.89 | Other bipolar disorder |
| 90 | 10 | F31.9 | Bipolar disorder, unspecified |
| 1. This set of codes is adopted in whole from the code set published by the Harvard eMERGE team in their bipolar phenotype pseudo code document “Bipolar Disorder (BD) Phenotype Algorithm” dated May 10,2018 (see also Castro 2015).  2. Codes in a patient’s record must match the listed codes exactly; codes with additional characters or digits are not valid matches. | | | |

| Table MED. Generic and brand names of antidepressant medications used to identify treatment for depression.1 | |
| --- | --- |
| **Generic name**2 | **Brand name**2 |
| AMITRIPTYLINE | Elavil, Endep, Amitril |
| AMITRIPTYLINE/ CHLORDIAZEPOXIDE | Limbitrol |
| AMITRIPTYLINE/ PERPHENAZINE | Duo-Vil, Etrafon, Triavil |
| AMOXAPINE | Asendin |
| BUPROPION | Aplenzin, Appbutamone, Budeprion, Buproban, Forfivo, Wellbutrin |
| CITALOPRAM | Celexa |
| CLOMIPRAMINE | Anafranil |
| DESIPRAMINE | Norpramin, Pertofrane |
| DESVENLAFAXINE | Pristiq |
| DOXEPIN | Adapin, Sinequan, Silenor |
| DULOXETINE | Cymbalta |
| ESCITALOPRAM | Lexapro |
| FLUOXETINE | Prozac, Gaboxetine, Rapiflux, Sarafem, Selfemra, Sentroxatine |
| FLUOXETINE/OLANZAPINE | Symbyax |
| FLUVOXAMINE | Luvox |
| IMIPRAMINE | Tofranil, Janimine |
| ISOCARBOXAZID | Marplan |
| MAPROTILINE | Ludiomil |
| MILNACIPRAN | Savella |
| MIRTAZAPINE | Remeron |
| NEFAZODONE | Serzone |
| NOMIFENSINE | Merital, Alival |
| NORTRIPTYLINE | Pamelor, Aventil, Aventyl |
| PAROXETINE | Paxil, Pexeva |
| PHENELZINE | Nardil |
| PROTRIPTYLINE | Vivactil |
| SELEGILINE | Eldepryl |
| SERTRALINE | Zoloft |
| TRANYLCYPROMINE | Parnate |
| TRIMIPRAMINE | Surmontil |
| VENLAFAXINE | Effexor |
| VILAZODONE | Viibryd |
| VORTIOXETINE | Trintellix, Brintellix |
| LEVOMILNACIPRAN | Fetzima |
| 1. These medications are adapted from a list curated by the Mental Health Research Network available on GitHub.  2. If dispensing data indicate *both* the brand name and the generic name, use *only* the brand name to qualify a dispensing; if *only* the generic name is available, use the generic name. Giving priority to brand name avoids misinterpreting medications with the same generic name use primarily to treat other conditions (e.g., the brand name drug “Zyban” is a form of BUPROPION used primarily for smoking cessation). | |

|  |  |  |  |
| --- | --- | --- | --- |
| Table ECT. Electroconvulsive therapy procedure codes (updated 4/17/2019).1 | | | |
| **Row** | **ICD era** | **ICD code**2 | **ICD description** |
| 1 | 9 | 94.26 | Subconvulsive electroshock therapy |
| 2 | 9 | 94.27 | Other electroshock therapy |
| 3 | 10 | GZB | Electroconvulsive therapy |
| **Row** | **Code type** | **Code** | **Code description** |
| 4 | CPT | 90870 | Electroconvulsive therapy (includes necessary monitoring) (Single Seizure per day) |
| 5 | CPT | 90871 | Multiple Seizures, per day. multiple seizures is also known as multiple monitored ECT (MMECT) |
| 1. These codes are adapted from list curated by the Mental Health Research Network available on GitHub.  2. To be included, the code appearing in a patient’s record must match the listed code exactly; codes with additional characters or digits are not valid matches. | | | |

| Table PSY. Procedure codes for delivery of psychotherapy. | | | |
| --- | --- | --- | --- |
| **Type** | **Code** | **Category** | **Description** |
| cpt4 | 90870 | Brain Stimulation Therapies | Electroconvulsive therapy |
| cpt4 | 90853 | Group Psychotherapy | Group psychotherapy (other than of a multiple-family group) |
| cpt4 | 90875 | Other MH Specialty | Individual Psychophysiological Therapy Incorporating Biofeedback Training by any Modality, 20-30 |
| cpt4 | 90876 | Other MH Specialty | Individual Psychophysiological Therapy Incorporating Biofeedback Training by any Modality, 45 |
| cpt4 | 90805 | Medication Management | Individual therapy with med mgt  20-30 min |
| cpt4 | 90807 | Medication Management | Individual therapy with med mgt 45-50 min |
| cpt4 | 90809 | Medication Management | Individual therapy with med mgt 75-80 min |
| cpt4 | 90823 | Other MH Specialty | Inpatient Interactive therapy 20–30 min |
| cpt4 | 90826 | Other MH Specialty | Inpatient Interactive therapy 45–50 min |
| cpt4 | 90828 | Other MH Specialty | Inpatient Interactive therapy 75–80 min |
| cpt4 | 90827 | Medication Management | Inpatient Interactive therapy with med mgt 45–50 min |
| cpt4 | 90816 | Other MH Specialty | Inpatient psychotherapy 20-30 min |
| cpt4 | 90818 | Individual Psychotherapy | Inpatient psychotherapy 45-50 min |
| cpt4 | 90821 | Individual Psychotherapy | Inpatient psychotherapy 75-80 min |
| cpt4 | 90817 | Medication Management | Inpatient psychotherapy with med mgt 20-30 min |
| cpt4 | 90819 | Individual Psychotherapy | Inpatient psychotherapy with med mgt 45-50 min |
| cpt4 | 90822 | Individual Psychotherapy | Inpatient psychotherapy with med mgt 75-80 min |
| cpt4 | 90857 | Group Psychotherapy | Interactive group psychotherapy |
| cpt4 | 90810 | Other MH Specialty | Interactive therapy 20–30 min |
| cpt4 | 90812 | Individual Psychotherapy | Interactive therapy 45–50 min |
| cpt4 | 90814 | Individual Psychotherapy | Interactive therapy 75 – 80 min |
| cpt4 | 90811 | Medication Management | Interactive therapy with med mgt 20–30 min |
| cpt4 | 90813 | Medication Management | Interactive therapy with med mgt 45–50 min |
| cpt4 | 90815 | Medication Management | Interactive therapy with med mgt 75 – 80 min |
| cpt4 | 90804 | Other MH Specialty | Outpatient psychotherapy 20-30 min |
| cpt4 | 90806 | Individual Psychotherapy | Outpatient psychotherapy 45-50 min |
| cpt4 | 90844 | Individual Psychotherapy | Outpatient psychotherapy 45-50 min (replaced by 90806) |
| cpt4 | 90808 | Individual Psychotherapy | Outpatient psychotherapy 75-80 min |
| cpt4 | 90840 | Individual Psychotherapy | Psychotherapy for crisis 30 min add-on |
| cpt4 | 90839 | Individual Psychotherapy | Psychotherapy for crisis, first 60 minutes |
| cpt4 | 90832 | Individual Psychotherapy | Psychotherapy, 30 min with patient and/or family member |
| cpt4 | 90833 | Individual Psychotherapy | Psychotherapy, 30 min with patient and/or family member with med mgt |
| cpt4 | 90834 | Individual Psychotherapy | Psychotherapy, 45 min with patient and/or family member |
| cpt4 | 90836 | Individual Psychotherapy | Psychotherapy, 45 min with patient and/or family member with med mgt |
| cpt4 | 90837 | Individual Psychotherapy | Psychotherapy, 60 min with patient and/or family member |
| cpt4 | 90838 | Individual Psychotherapy | Psychotherapy, 60 min with patient and/or family member with med mgt |
| cpt4 | 90867 | Brain Stimulation Therapies | Transcranial magnetic stimulation (TMS) |
| cpt4 | 90868 | Brain Stimulation Therapies | Transcranial magnetic stimulation (TMS) |
| cpt4 | 90869 | Brain Stimulation Therapies | Transcranial magnetic stimulation (TMS) |

| Table ANX. Anxiety diagnosis codes.1 | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**2 | **ICD description** |
| 1 | 9 | 293.84 | ANXIETY DISORDER OTH DIS |
| 2 | 9 | 300.00 | ANXIETY STATE NOS |
| 3 | 9 | 300.01 | PANIC DIS W/O AGORPHOBIA |
| 4 | 9 | 300.02 | GENERALIZED ANXIETY DIS |
| 5 | 9 | 300.09 | ANXIETY STATE NEC |
| 6 | 9 | 300.20 | PHOBIA NOS |
| 7 | 9 | 300.21 | AGORAPHOBIA W PANIC DIS |
| 8 | 9 | 300.22 | AGORAPHOBIA W/O PANIC |
| 9 | 9 | 300.23 | SOCIAL PHOBIA |
| 10 | 9 | 300.29 | ISOLATED/SPEC PHOBIA NEC |
| 11 | 9 | 300.3 | OBSESSIVE-COMPULSIVE DIS |
| 12 | 9 | 308.0 | STRESS REACT, EMOTIONAL |
| 13 | 9 | 308.1 | STRESS REACTION, FUGUE |
| 14 | 9 | 308.2 | STRESS REACT, PSYCHOMOT |
| 15 | 9 | 308.3 | ACUTE STRESS REACT NEC |
| 16 | 9 | 308.4 | STRESS REACT, MIXED DIS |
| 17 | 9 | 308.9 | ACUTE STRESS REACT NOS |
| 18 | 9 | 309.21 | SEPARATION ANXIETY |
| 19 | 9 | 309.24 | ADJUSTMENT DIS W ANXIETY |
| 20 | 9 | 309.28 | ADJUST DIS W ANXIETY/DEP |
| 21 | 9 | 309.81 | POSTTRAUMATIC STRESS DIS |
| 22 | 10 | F06.4 | ANXIETY DISORDER DUE TO KNOWN PHYSIOLOGICAL CONDITION |
| 23 | 10 | F10.180 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED ANXIETY DISORDER |
| 24 | 10 | F10.280 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED ANXIETY DISORDER |
| 25 | 10 | F10.980 | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED ANXIETY DISORDER |
| 26 | 10 | F12.180 | CANNABIS ABUSE WITH CANNABIS-INDUCED ANXIETY DISORDER |
| 27 | 10 | F12.280 | CANNABIS DEPENDENCE WITH CANNABIS-INDUCED ANXIETY DISORDER |
| 28 | 10 | F12.980 | CANNABIS USE, UNSPECIFIED WITH ANXIETY DISORDER |
| 29 | 10 | F13.180 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER |
| 30 | 10 | F13.280 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER |
| 31 | 10 | F13.980 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER |
| 32 | 10 | F14.180 | COCAINE ABUSE WITH COCAINE-INDUCED ANXIETY DISORDER |
| 33 | 10 | F14.280 | COCAINE DEPENDENCE WITH COCAINE-INDUCED ANXIETY DISORDER |
| 34 | 10 | F14.980 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED ANXIETY DISORDER |
| 35 | 10 | F15.180 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED ANXIETY DISORDER |
| 36 | 10 | F15.280 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED ANXIETY DISORDER |
| 37 | 10 | F15.980 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER |
| 38 | 10 | F16.180 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER |
| 39 | 10 | F16.280 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER |
| 40 | 10 | F16.980 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER |
| 41 | 10 | F18.180 | INHALANT ABUSE WITH INHALANT-INDUCED ANXIETY DISORDER |
| 42 | 10 | F18.280 | INHALANT DEPENDENCE WITH INHALANT-INDUCED ANXIETY DISORDER |
| 43 | 10 | F18.980 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED ANXIETY DISORDER |
| 44 | 10 | F19.180 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER |
| 45 | 10 | F19.280 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER |
| 46 | 10 | F19.980 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER |
| 47 | 10 | F40.00 | AGORAPHOBIA, UNSPECIFIED |
| 48 | 10 | F40.01 | AGORAPHOBIA WITH PANIC DISORDER |
| 49 | 10 | F40.02 | AGORAPHOBIA WITHOUT PANIC DISORDER |
| 50 | 10 | F40.10 | SOCIAL PHOBIA, UNSPECIFIED |
| 51 | 10 | F40.11 | SOCIAL PHOBIA, GENERALIZED |
| 52 | 10 | F40.210 | ARACHNOPHOBIA |
| 53 | 10 | F40.218 | OTHER ANIMAL TYPE PHOBIA |
| 54 | 10 | F40.220 | FEAR OF THUNDERSTORMS |
| 55 | 10 | F40.228 | OTHER NATURAL ENVIRONMENT TYPE PHOBIA |
| 56 | 10 | F40.230 | FEAR OF BLOOD |
| 57 | 10 | F40.231 | FEAR OF INJECTIONS AND TRANSFUSIONS |
| 58 | 10 | F40.232 | FEAR OF OTHER MEDICAL CARE |
| 59 | 10 | F40.233 | FEAR OF INJURY |
| 60 | 10 | F40.240 | CLAUSTROPHOBIA |
| 61 | 10 | F40.241 | ACROPHOBIA |
| 62 | 10 | F40.242 | FEAR OF BRIDGES |
| 63 | 10 | F40.243 | FEAR OF FLYING |
| 64 | 10 | F40.248 | OTHER SITUATIONAL TYPE PHOBIA |
| 65 | 10 | F40.290 | ANDROPHOBIA |
| 66 | 10 | F40.291 | GYNEPHOBIA |
| 67 | 10 | F40.298 | OTHER SPECIFIED PHOBIA |
| 68 | 10 | F40.8 | OTHER PHOBIC ANXIETY DISORDERS |
| 69 | 10 | F40.9 | PHOBIC ANXIETY DISORDER, UNSPECIFIED |
| 70 | 10 | F41.0 | PANIC DISORDER [EPISODIC PAROXYSMAL ANXIETY] WITHOUT AGORAPHOBIA |
| 71 | 10 | F41.0 | PANIC DISORDER [EPISODIC PAROXYSMAL ANXIETY] |
| 72 | 10 | F41.1 | GENERALIZED ANXIETY DISORDER |
| 73 | 10 | F41.3 | OTHER MIXED ANXIETY DISORDERS |
| 74 | 10 | F41.8 | OTHER SPECIFIED ANXIETY DISORDERS |
| 75 | 10 | F41.9 | ANXIETY DISORDER, UNSPECIFIED |
| 76 | 10 | F42 | OBSESSIVE-COMPULSIVE DISORDER |
| 77 | 10 | F42.2 | MIXED OBSESSIONAL THOUGHTS AND ACTS |
| 78 | 10 | F42.3 | HOARDING DISORDER |
| 79 | 10 | F42.4 | EXCORIATION (SKIN-PICKING) DISORDER |
| 80 | 10 | F42.8 | OTHER OBSESSIVE-COMPULSIVE DISORDER |
| 81 | 10 | F42.9 | OBSESSIVE-COMPULSIVE DISORDER, UNSPECIFIED |
| 82 | 10 | F43.0 | ACUTE STRESS REACTION |
| 83 | 10 | F43.10 | POST-TRAUMATIC STRESS DISORDER, UNSPECIFIED |
| 84 | 10 | F43.11 | POST-TRAUMATIC STRESS DISORDER, ACUTE |
| 85 | 10 | F43.12 | POST-TRAUMATIC STRESS DISORDER, CHRONIC |
| 86 | 10 | F43.20 | ADJUSTMENT DISORDER, UNSPECIFIED |
| 87 | 10 | F43.21 | ADJUSTMENT DISORDER WITH DEPRESSED MOOD |
| 88 | 10 | F43.22 | ADJUSTMENT DISORDER WITH ANXIETY |
| 89 | 10 | F43.23 | ADJUSTMENT DISORDER WITH MIXED ANXIETY AND DEPRESSED MOOD |
| 90 | 10 | F43.24 | ADJUSTMENT DISORDER WITH DISTURBANCE OF CONDUCT |
| 91 | 10 | F43.25 | ADJUSTMENT DISORDER WITH MIXED DISTURBANCE OF EMOTIONS AND CONDUCT |
| 92 | 10 | F43.29 | ADJUSTMENT DISORDER WITH OTHER SYMPTOMS |
| 93 | 10 | F43.8 | OTHER REACTIONS TO SEVERE STRESS |
| 94 | 10 | F43.9 | REACTION TO SEVERE STRESS, UNSPECIFIED |
| 95 | 10 | F93.0 | SEPARATION ANXIETY DISORDER OF CHILDHOOD |
| 1. These codes are adapted from list curated by the Mental Health Research Network available on GitHub.  2. To be included, the code appearing in a patient’s record must match the listed code exactly; codes with additional characters or digits are not valid matches. | | | |

| Table SCH. Schizophrenia and other psychotic (excluding bipolar) disorder diagnosis codes.1 | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**2 | **ICD description** |
| *Schizophrenia* | | | |
| 1 | 9 | 295.00 | SIMPL SCHIZOPHREN-UNSPEC |
| 2 | 9 | 295.01 | SIMPL SCHIZOPHREN-SUBCHR |
| 3 | 9 | 295.02 | SIMPLE SCHIZOPHREN-CHR |
| 4 | 9 | 295.03 | SIMP SCHIZ-SUBCHR/EXACER |
| 5 | 9 | 295.04 | SIMPL SCHIZO-CHR/EXACERB |
| 6 | 9 | 295.05 | SIMPL SCHIZOPHREN-REMISS |
| 7 | 9 | 295.10 | HEBEPHRENIA-UNSPEC |
| 8 | 9 | 295.11 | HEBEPHRENIA-SUBCHRONIC |
| 9 | 9 | 295.12 | HEBEPHRENIA-CHRONIC |
| 10 | 9 | 295.13 | HEBEPHREN-SUBCHR/EXACERB |
| 11 | 9 | 295.14 | HEBEPHRENIA-CHR/EXACERB |
| 12 | 9 | 295.15 | HEBEPHRENIA-REMISSION |
| 13 | 9 | 295.20 | CATATONIA-UNSPEC |
| 14 | 9 | 295.21 | CATATONIA-SUBCHRONIC |
| 15 | 9 | 295.22 | CATATONIA-CHRONIC |
| 16 | 9 | 295.23 | CATATONIA-SUBCHR/EXACERB |
| 17 | 9 | 295.24 | CATATONIA-CHR/EXACERB |
| 18 | 9 | 295.25 | CATATONIA-REMISSION |
| 19 | 9 | 295.30 | PARANOID SCHIZO-UNSPEC |
| 20 | 9 | 295.31 | PARANOID SCHIZO-SUBCHR |
| 21 | 9 | 295.32 | PARANOID SCHIZO-CHRONIC |
| 22 | 9 | 295.33 | PARAN SCHIZO-SUBCHR/EXAC |
| 23 | 9 | 295.34 | PARAN SCHIZO-CHR/EXACERB |
| 24 | 9 | 295.35 | PARANOID SCHIZO-REMISS |
| 25 | 9 | 295.40 | SCHIZOPHRENIFORM DIS NOS |
| 26 | 9 | 295.41 | SCHIZOPHRENIC DIS-SUBCHR |
| 27 | 9 | 295.42 | SCHIZOPHREN DIS-CHRONIC |
| 28 | 9 | 295.43 | SCHIZO DIS-SUBCHR/EXACER |
| 29 | 9 | 295.44 | SCHIZOPHR DIS-CHR/EXACER |
| 30 | 9 | 295.45 | SCHIZOPHRENIC DIS-REMISS |
| 31 | 9 | 295.50 | LATENT SCHIZOPHREN-UNSP |
| 32 | 9 | 295.51 | LAT SCHIZOPHREN-SUBCHR |
| 33 | 9 | 295.52 | LATENT SCHIZOPHREN-CHR |
| 34 | 9 | 295.53 | LAT SCHIZO-SUBCHR/EXACER |
| 35 | 9 | 295.54 | LATENT SCHIZO-CHR/EXACER |
| 36 | 9 | 295.55 | LAT SCHIZOPHREN-REMISS |
| 37 | 9 | 295.60 | SCHIZOPHR DIS RESID NOS |
| 38 | 9 | 295.61 | SCHIZOPH DIS RESID-SUBCH |
| 39 | 9 | 295.62 | SCHIZOPHR DIS RESID-CHR |
| 40 | 9 | 295.63 | SCHIZO RESID SUBCHR/EXAC |
| 41 | 9 | 295.64 | SCHIZOPH RESID-CHRO/EXAC |
| 42 | 9 | 295.65 | SCHIZOPH DIS RESID-REMIS |
| 43 | 9 | 295.70 | SCHIZOAFFECTIVE DIS NOS |
| 44 | 9 | 295.71 | SCHIZOAFFECTV DIS-SUBCHR |
| 45 | 9 | 295.72 | SCHIZOAFFECTIVE DIS-CHR |
| 46 | 9 | 295.73 | SCHIZOAFF DIS-SUBCH/EXAC |
| 47 | 9 | 295.74 | SCHIZOAFFTV DIS-CHR/EXAC |
| 48 | 9 | 295.75 | SCHIZOAFFECTVE DIS-REMIS |
| 49 | 9 | 295.80 | SCHIZOPHRENIA NEC-UNSPEC |
| 50 | 9 | 295.81 | SCHIZOPHRENIA NEC-SUBCHR |
| 51 | 9 | 295.82 | SCHIZOPHRENIA NEC-CHR |
| 52 | 9 | 295.83 | SCHIZO NEC-SUBCHR/EXACER |
| 53 | 9 | 295.84 | SCHIZO NEC-CHR/EXACERB |
| 54 | 9 | 295.85 | SCHIZOPHRENIA NEC-REMISS |
| 55 | 9 | 29.590 | SCHIZOPHRENIA NOS-UNSPEC |
| 56 | 9 | 295.91 | SCHIZOPHRENIA NOS-SUBCHR |
| 57 | 9 | 295.92 | SCHIZOPHRENIA NOS-CHR |
| 58 | 9 | 295.93 | SCHIZO NOS-SUBCHR/EXACER |
| 59 | 9 | 295.94 | SCHIZO NOS-CHR/EXACERB |
| 60 | 9 | 295.95 | SCHIZOPHRENIA NOS-REMISS |
| 61 | 9 | 301.20 | SCHIZOID PERSONALITY NOS |
| 62 | 9 | 301.22 | SCHIZOTYPAL PERSON DIS |
| 63 | 10 | F20.0 | PARANOID SCHIZOPHRENIA |
| 64 | 10 | F20.1 | DISORGANIZED SCHIZOPHRENIA |
| 65 | 10 | F20.2 | CATATONIC SCHIZOPHRENIA |
| 66 | 10 | F20.3 | UNDIFFERENTIATED SCHIZOPHRENIA |
| 67 | 10 | F20.5 | RESIDUAL SCHIZOPHRENIA |
| 68 | 10 | F20.81 | SCHIZOPHRENIFORM DISORDER |
| 69 | 10 | F20.89 | OTHER SCHIZOPHRENIA |
| 70 | 10 | F20.9 | SCHIZOPHRENIA, UNSPECIFIED |
| 71 | 10 | F21 | SCHIZOTYPAL DISORDER |
| 72 | 10 | F25.0 | SCHIZOAFFECTIVE DISORDER, BIPOLAR TYPE |
| 73 | 10 | F25.1 | SCHIZOAFFECTIVE DISORDER, DEPRESSIVE TYPE |
| 74 | 10 | F25.8 | OTHER SCHIZOAFFECTIVE DISORDERS |
| 75 | 10 | F25.9 | SCHIZOAFFECTIVE DISORDER, UNSPECIFIED |
| 76 | 10 | F60.1 | SCHIZOID PERSONALITY DISORDER |
| *Other psychotic disorders (excluding bipolar disorder)* | | | |
| 77 | 9 | 297.0 | PARANOID STATE, SIMPLE |
| 78 | 9 | 297.1 | DELUSIONAL DISORDER |
| 79 | 9 | 297.2 | PARAPHRENIA |
| 80 | 9 | 297.3 | SHARED PSYCHOTIC DISORD |
| 81 | 9 | 297.8 | PARANOID STATES NEC |
| 82 | 9 | 297.9 | PARANOID STATE NOS |
| 83 | 9 | 298.0 | REACT DEPRESS PSYCHOSIS |
| 84 | 9 | 298.1 | EXCITATIV TYPE PSYCHOSIS |
| 85 | 9 | 298.2 | REACTIVE CONFUSION |
| 86 | 9 | 298.3 | ACUTE PARANOID REACTION |
| 87 | 9 | 298.4 | PSYCHOGEN PARANOID PSYCH |
| 88 | 9 | 298.8 | REACT PSYCHOSIS NEC/NOS |
| 89 | 9 | 298.9 | PSYCHOSIS NOS |
| 90 | 10 | F22\* | DELUSIONAL DISORDERS |
| 91 | 10 | F23\* | BRIEF PSYCHOTIC DISORDER |
| 92 | 10 | F24\* | SHARED PSYCHOTIC DISORDER |
| 93 | 10 | F28\* | OTHER PSYCHOTIC DISORDER NOT DUE TO A SUBSTANCE OR KNOWN PHYSIOLOGICAL CONDITION |
| 94 | 10 | F29\* | UNSPECIFIED PSYCHOSIS NOT DUE TO A SUBSTANCE OR KNOWN PHYSIOLOGICAL CONDITION |
| 1. These codes are adapted from list curated by the Mental Health Research Network available on GitHub.  2. To be included, the code appearing in a patient’s record must match the listed code exactly; codes with additional characters or digits are not valid matches. | | | |

| Table SEZ. Seizure diagnosis codes. | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**1 | **ICD description** |
| 1 | 9 | 345.\* | Epilepsy and recurrent seizures |
| 2 | 9 | 780.33 | Post traumatic seizures |
| 3 | 9 | 780.39 | Other convulsions |
| 4 | 10 | G40\* | Epilepsy and recurrent seizures; other seizures |
| 5 | 10 | R561 | Post traumatic seizures |
| 1. Presence of an asterisk in a code indicates any code beginning with the characters to the left of the asterisk qualifies. Codes without an asterisk must match the listed code exactly. | | | |

| Table SUD. Substance use disorder diagnoses.1 | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**2 | **ICD description** |
| 1 | 9 | 292.0 | DRUG WITHDRAWAL |
| 2 | 9 | 292.11 | DRUG PSYCH DISOR W DELUS |
| 3 | 9 | 292.12 | DRUG PSY DIS W HALLUCIN |
| 4 | 9 | 292.2 | PATHOLOGIC DRUG INTOX |
| 5 | 9 | 292.81 | DRUG-INDUCED DELIRIUM |
| 6 | 9 | 292.82 | DRUG PERSISTING DEMENTIA |
| 7 | 9 | 292.83 | DRUG PERSIST AMNESTC DIS |
| 8 | 9 | 292.84 | DRUG-INDUCED MOOD DISORD |
| 9 | 9 | 292.85 | DRUG INDUCED SLEEP DISOR |
| 10 | 9 | 292.89 | DRUG MENTAL DISORDER NEC |
| 11 | 9 | 292.9 | DRUG MENTAL DISORDER NOS |
| 12 | 9 | 304.00 | OPIOID DEPENDENCE-UNSPEC |
| 13 | 9 | 304.01 | OPIOID DEPENDENCE-CONTIN |
| 14 | 9 | 304.02 | OPIOID DEPENDENCE-EPISOD |
| 15 | 9 | 304.03 | OPIOID DEPENDENCE-REMISS |
| 16 | 9 | 304.10 | SED,HYP,ANXIOLYT DEP-NOS |
| 17 | 9 | 304.11 | SED,HYP,ANXIOLYT DEP-CON |
| 18 | 9 | 304.12 | SED,HYP,ANXIOLYT DEP-EPI |
| 19 | 9 | 304.13 | SED,HYP,ANXIOLYT DEP-REM |
| 20 | 9 | 304.20 | COCAINE DEPEND-UNSPEC |
| 21 | 9 | 304.21 | COCAINE DEPEND-CONTIN |
| 22 | 9 | 304.22 | COCAINE DEPEND-EPISODIC |
| 23 | 9 | 304.23 | COCAINE DEPEND-REMISS |
| 24 | 9 | 304.30 | CANNABIS DEPEND-UNSPEC |
| 25 | 9 | 304.31 | CANNABIS DEPEND-CONTIN |
| 26 | 9 | 304.32 | CANNABIS DEPEND-EPISODIC |
| 27 | 9 | 304.33 | CANNABIS DEPEND-REMISS |
| 28 | 9 | 304.40 | AMPHETAMIN DEPEND-UNSPEC |
| 29 | 9 | 304.41 | AMPHETAMIN DEPEND-CONTIN |
| 30 | 9 | 304.42 | AMPHETAMIN DEPEND-EPISOD |
| 31 | 9 | 304.43 | AMPHETAMIN DEPEND-REMISS |
| 32 | 9 | 304.50 | HALLUCINOGEN DEP-UNSPEC |
| 33 | 9 | 304.51 | HALLUCINOGEN DEP-CONTIN |
| 34 | 9 | 304.52 | HALLUCINOGEN DEP-EPISOD |
| 35 | 9 | 304.53 | HALLUCINOGEN DEP-REMISS |
| 36 | 9 | 304.60 | DRUG DEPEND NEC-UNSPEC |
| 37 | 9 | 304.61 | DRUG DEPEND NEC-CONTIN |
| 38 | 9 | 304.62 | DRUG DEPEND NEC-EPISODIC |
| 39 | 9 | 304.63 | DRUG DEPEND NEC-IN REM |
| 40 | 9 | 304.70 | OPIOID/OTHER DEP-UNSPEC |
| 41 | 9 | 304.71 | OPIOID/OTHER DEP-CONTIN |
| 42 | 9 | 304.72 | OPIOID/OTHER DEP-EPISOD |
| 43 | 9 | 304.73 | OPIOID/OTHER DEP-REMISS |
| 44 | 9 | 304.80 | COMB DRUG DEP NEC-UNSPEC |
| 45 | 9 | 304.81 | COMB DRUG DEP NEC-CONTIN |
| 46 | 9 | 304.82 | COMB DRUG DEP NEC-EPISOD |
| 47 | 9 | 304.83 | COMB DRUG DEP NEC-REMISS |
| 48 | 9 | 304.90 | DRUG DEPEND NOS-UNSPEC |
| 49 | 9 | 304.91 | DRUG DEPEND NOS-CONTIN |
| 50 | 9 | 304.92 | DRUG DEPEND NOS-EPISODIC |
| 51 | 9 | 304.93 | DRUG DEPEND NOS-REMISS |
| 52 | 9 | 305.20 | CANNABIS ABUSE-UNSPEC |
| 53 | 9 | 305.21 | CANNABIS ABUSE-CONTIN |
| 54 | 9 | 305.22 | CANNABIS ABUSE-EPISODIC |
| 55 | 9 | 305.30 | HALLUCINOG ABUSE-UNSPEC |
| 56 | 9 | 305.31 | HALLUCINOG ABUSE-CONTIN |
| 57 | 9 | 305.32 | HALLUCINOG ABUSE-EPISOD |
| 58 | 9 | 305.40 | SED,HYP,ANXIOLYTC AB-NOS |
| 59 | 9 | 305.41 | SED,HYP,ANXIOLYTC AB-CON |
| 60 | 9 | 305.42 | SED,HYP,ANXIOLYTC AB-EPI |
| 61 | 9 | 305.50 | OPIOID ABUSE-UNSPEC |
| 62 | 9 | 305.51 | OPIOID ABUSE-CONTINUOUS |
| 63 | 9 | 305.52 | OPIOID ABUSE-EPISODIC |
| 64 | 9 | 305.60 | COCAINE ABUSE-UNSPEC |
| 65 | 9 | 305.61 | COCAINE ABUSE-CONTINUOUS |
| 66 | 9 | 305.62 | COCAINE ABUSE-EPISODIC |
| 67 | 9 | 305.70 | AMPHETAMINE ABUSE-UNSPEC |
| 68 | 9 | 305.71 | AMPHETAMINE ABUSE-CONTIN |
| 69 | 9 | 305.72 | AMPHETAMINE ABUSE-EPISOD |
| 70 | 9 | 305.80 | ANTIDEPRESS ABUSE-UNSPEC |
| 71 | 9 | 305.81 | ANTIDEPRESS ABUSE-CONTIN |
| 72 | 9 | 305.82 | ANTIDEPRESS ABUSE-EPISOD |
| 73 | 9 | 305.90 | DRUG ABUSE NEC-UNSPEC |
| 74 | 9 | 305.91 | DRUG ABUSE NEC-CONTIN |
| 75 | 9 | 305.92 | DRUG ABUSE NEC-EPISODIC |
| 76 | 10 | F11.10 | OPIOID ABUSE, UNCOMPLICATED |
| 77 | 10 | F11.120 | OPIOID ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 78 | 10 | F11.121 | OPIOID ABUSE WITH INTOXICATION DELIRIUM |
| 79 | 10 | F11.122 | OPIOID ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 80 | 10 | F11.129 | OPIOID ABUSE WITH INTOXICATION, UNSPECIFIED |
| 81 | 10 | F11.14 | OPIOID ABUSE WITH OPIOID-INDUCED MOOD DISORDER |
| 82 | 10 | F11.150 | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 83 | 10 | F11.151 | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 84 | 10 | F11.159 | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 85 | 10 | F11.181 | OPIOID ABUSE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION |
| 86 | 10 | F11.182 | OPIOID ABUSE WITH OPIOID-INDUCED SLEEP DISORDER |
| 87 | 10 | F11.188 | OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDER |
| 88 | 10 | F11.19 | OPIOID ABUSE WITH UNSPECIFIED OPIOID-INDUCED DISORDER |
| 89 | 10 | F11.20 | OPIOID DEPENDENCE, UNCOMPLICATED |
| 90 | 10 | F11.220 | OPIOID DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 91 | 10 | F11.221 | OPIOID DEPENDENCE WITH INTOXICATION DELIRIUM |
| 92 | 10 | F11.222 | OPIOID DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 93 | 10 | F11.229 | OPIOID DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 94 | 10 | F11.23 | OPIOID DEPENDENCE WITH WITHDRAWAL |
| 95 | 10 | F11.24 | OPIOID DEPENDENCE WITH OPIOID-INDUCED MOOD DISORDER |
| 96 | 10 | F11.250 | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 97 | 10 | F11.251 | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 98 | 10 | F11.259 | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 99 | 10 | F11.281 | OPIOID DEPENDENCE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION |
| 100 | 10 | F11.282 | OPIOID DEPENDENCE WITH OPIOID-INDUCED SLEEP DISORDER |
| 101 | 10 | F11288 | OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDER |
| 102 | 10 | F11.29 | OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED DISORDER |
| 103 | 10 | F11.90 | OPIOID USE, UNSPECIFIED, UNCOMPLICATED |
| 104 | 10 | F11.920 | OPIOID USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 105 | 10 | F11.921 | OPIOID USE, UNSPECIFIED WITH INTOXICATION DELIRIUM |
| 106 | 10 | F11.922 | OPIOID USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 107 | 10 | F11.929 | OPIOID USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 108 | 10 | F11.93 | OPIOID USE, UNSPECIFIED WITH WITHDRAWAL |
| 109 | 10 | F11.94 | OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED MOOD DISORDER |
| 110 | 10 | F11.950 | OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 111 | 10 | F11.951 | OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 112 | 10 | F11.959 | OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 113 | 10 | F11.981 | OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED SEXUAL DYSFUNCTION |
| 114 | 10 | F11.982 | OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED SLEEP DISORDER |
| 115 | 10 | F11.988 | OPIOID USE, UNSPECIFIED WITH OTHER OPIOID-INDUCED DISORDER |
| 116 | 10 | F11.99 | OPIOID USE, UNSPECIFIED WITH UNSPECIFIED OPIOID-INDUCED DISORDER |
| 117 | 10 | F12.10 | CANNABIS ABUSE, UNCOMPLICATED |
| 118 | 10 | F12.120 | CANNABIS ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 119 | 10 | F12.121 | CANNABIS ABUSE WITH INTOXICATION DELIRIUM |
| 120 | 10 | F12.122 | CANNABIS ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 121 | 10 | F12.129 | CANNABIS ABUSE WITH INTOXICATION, UNSPECIFIED |
| 122 | 10 | F12.150 | CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH DELUSIONS |
| 123 | 10 | F12.151 | CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 124 | 10 | F12.159 | CANNABIS ABUSE WITH PSYCHOTIC DISORDER, UNSPECIFIED |
| 125 | 10 | F12.180 | CANNABIS ABUSE WITH CANNABIS-INDUCED ANXIETY DISORDER |
| 126 | 10 | F12.188 | CANNABIS ABUSE WITH OTHER CANNABIS-INDUCED DISORDER |
| 127 | 10 | F12.19 | CANNABIS ABUSE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER |
| 128 | 10 | F12.20 | CANNABIS DEPENDENCE, UNCOMPLICATED |
| 129 | 10 | F12.220 | CANNABIS DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 130 | 10 | F12.221 | CANNABIS DEPENDENCE WITH INTOXICATION DELIRIUM |
| 131 | 10 | F12.222 | CANNABIS DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 132 | 10 | F12.229 | CANNABIS DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 133 | 10 | F12.250 | CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH DELUSIONS |
| 134 | 10 | F12.251 | CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 135 | 10 | F12.259 | CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER, UNSPECIFIED |
| 136 | 10 | F12.280 | CANNABIS DEPENDENCE WITH CANNABIS-INDUCED ANXIETY DISORDER |
| 137 | 10 | F12.288 | CANNABIS DEPENDENCE WITH OTHER CANNABIS-INDUCED DISORDER |
| 138 | 10 | F12.29 | CANNABIS DEPENDENCE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER |
| 139 | 10 | F12.90 | CANNABIS USE, UNSPECIFIED, UNCOMPLICATED |
| 140 | 10 | F12.920 | CANNABIS USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 141 | 10 | F12.921 | CANNABIS USE, UNSPECIFIED WITH INTOXICATION DELIRIUM |
| 142 | 10 | F12.922 | CANNABIS USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 143 | 10 | F12.929 | CANNABIS USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 144 | 10 | F12.950 | CANNABIS USE, UNSPECIFIED WITH PSYCHOTIC DISORDER WITH DELUSIONS |
| 145 | 10 | F12.951 | CANNABIS USE, UNSPECIFIED WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 146 | 10 | F12.959 | CANNABIS USE, UNSPECIFIED WITH PSYCHOTIC DISORDER, UNSPECIFIED |
| 147 | 10 | F12.980 | CANNABIS USE, UNSPECIFIED WITH ANXIETY DISORDER |
| 148 | 10 | F12.988 | CANNABIS USE, UNSPECIFIED WITH OTHER CANNABIS-INDUCED DISORDER |
| 149 | 10 | F12.99 | CANNABIS USE, UNSPECIFIED WITH UNSPECIFIED CANNABIS-INDUCED DISORDER |
| 150 | 10 | F13.10 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNCOMPLICATED |
| 151 | 10 | F13.120 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 152 | 10 | F13.121 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION DELIRIUM |
| 153 | 10 | F13.129 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNSPECIFIED |
| 154 | 10 | F13.14 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER |
| 155 | 10 | F13.150 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 156 | 10 | F13.151 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 157 | 10 | F13.159 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 158 | 10 | F13.180 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER |
| 159 | 10 | F13.181 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION |
| 160 | 10 | F13.182 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER |
| 161 | 10 | F13.188 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER |
| 162 | 10 | F13.19 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER |
| 163 | 10 | F13.20 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED |
| 164 | 10 | F13.220 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 165 | 10 | F13.221 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION DELIRIUM |
| 166 | 10 | F13.229 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 167 | 10 | F13.230 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED |
| 168 | 10 | F13.231 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL DELIRIUM |
| 169 | 10 | F13.232 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE |
| 170 | 10 | F13.239 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED |
| 171 | 10 | F13.24 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER |
| 172 | 10 | F13.250 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 173 | 10 | F13.251 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 174 | 10 | F13.259 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 175 | 10 | F13.26 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING AMNESTIC DISORDER |
| 176 | 10 | F13.27 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING DEMENTIA |
| 177 | 10 | F13.280 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER |
| 178 | 10 | F13.281 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION |
| 179 | 10 | F13.282 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER |
| 180 | 10 | F13.288 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER |
| 181 | 10 | F13.29 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER |
| 182 | 10 | F13.90 | SEDATIVE, HYPNOTIC, OR ANXIOLYTIC USE, UNSPECIFIED, UNCOMPLICATED |
| 183 | 10 | F13.920 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 184 | 10 | F13.921 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH INTOXICATION DELIRIUM |
| 185 | 10 | F13.929 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 186 | 10 | F13.930 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL, UNCOMPLICATED |
| 187 | 10 | F13.931 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL DELIRIUM |
| 188 | 10 | F13.932 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCES |
| 189 | 10 | F13.939 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL, UNSPECIFIED |
| 190 | 10 | F13.94 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER |
| 191 | 10 | F13.950 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 192 | 10 | F13.951 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 193 | 10 | F13.959 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 194 | 10 | F13.96 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING AMNESTIC DISORDER |
| 195 | 10 | F13.97 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING DEMENTIA |
| 196 | 10 | F13.980 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER |
| 197 | 10 | F13.981 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION |
| 198 | 10 | F13.982 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER |
| 199 | 10 | F13.988 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER |
| 200 | 10 | F13.99 | SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER |
| 201 | 10 | F14.10 | COCAINE ABUSE, UNCOMPLICATED |
| 202 | 10 | F14.120 | COCAINE ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 203 | 10 | F14.121 | COCAINE ABUSE WITH INTOXICATION WITH DELIRIUM |
| 204 | 10 | F14.122 | COCAINE ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 205 | 10 | F14.129 | COCAINE ABUSE WITH INTOXICATION, UNSPECIFIED |
| 206 | 10 | F14.14 | COCAINE ABUSE WITH COCAINE-INDUCED MOOD DISORDER |
| 207 | 10 | F14.150 | COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 208 | 10 | F14.151 | COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 209 | 10 | F14.159 | COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 210 | 10 | F14.180 | COCAINE ABUSE WITH COCAINE-INDUCED ANXIETY DISORDER |
| 211 | 10 | F14.181 | COCAINE ABUSE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION |
| 212 | 10 | F14.182 | COCAINE ABUSE WITH COCAINE-INDUCED SLEEP DISORDER |
| 213 | 10 | F14.188 | COCAINE ABUSE WITH OTHER COCAINE-INDUCED DISORDER |
| 214 | 10 | F14.19 | COCAINE ABUSE WITH UNSPECIFIED COCAINE-INDUCED DISORDER |
| 215 | 10 | F14.20 | COCAINE DEPENDENCE, UNCOMPLICATED |
| 216 | 10 | F14.220 | COCAINE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 217 | 10 | F14.221 | COCAINE DEPENDENCE WITH INTOXICATION DELIRIUM |
| 218 | 10 | F14.222 | COCAINE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 219 | 10 | F14.229 | COCAINE DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 220 | 10 | F14.23 | COCAINE DEPENDENCE WITH WITHDRAWAL |
| 221 | 10 | F14.24 | COCAINE DEPENDENCE WITH COCAINE-INDUCED MOOD DISORDER |
| 222 | 10 | F14.250 | COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 223 | 10 | F14.251 | COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 224 | 10 | F14.259 | COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 225 | 10 | F14.280 | COCAINE DEPENDENCE WITH COCAINE-INDUCED ANXIETY DISORDER |
| 226 | 10 | F14.281 | COCAINE DEPENDENCE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION |
| 227 | 10 | F14.282 | COCAINE DEPENDENCE WITH COCAINE-INDUCED SLEEP DISORDER |
| 228 | 10 | F14.288 | COCAINE DEPENDENCE WITH OTHER COCAINE-INDUCED DISORDER |
| 229 | 10 | F14.29 | COCAINE DEPENDENCE WITH UNSPECIFIED COCAINE-INDUCED DISORDER |
| 230 | 10 | F14.90 | COCAINE USE, UNSPECIFIED, UNCOMPLICATED |
| 231 | 10 | F14.920 | COCAINE USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 232 | 10 | F14.921 | COCAINE USE, UNSPECIFIED WITH INTOXICATION DELIRIUM |
| 233 | 10 | F14.922 | COCAINE USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 234 | 10 | F14.929 | COCAINE USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 235 | 10 | F14.94 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED MOOD DISORDER |
| 236 | 10 | F14.950 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 237 | 10 | F14.951 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 238 | 10 | F14.959 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 239 | 10 | F14.980 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED ANXIETY DISORDER |
| 240 | 10 | F14.981 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED SEXUAL DYSFUNCTION |
| 241 | 10 | F14.982 | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED SLEEP DISORDER |
| 242 | 10 | F14.988 | COCAINE USE, UNSPECIFIED WITH OTHER COCAINE-INDUCED DISORDER |
| 243 | 10 | F14.99 | COCAINE USE, UNSPECIFIED WITH UNSPECIFIED COCAINE-INDUCED DISORDER |
| 244 | 10 | F15.10 | OTHER STIMULANT ABUSE, UNCOMPLICATED |
| 245 | 10 | F15.120 | OTHER STIMULANT ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 246 | 10 | F15.121 | OTHER STIMULANT ABUSE WITH INTOXICATION DELIRIUM |
| 247 | 10 | F15.122 | OTHER STIMULANT ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 248 | 10 | F15.129 | OTHER STIMULANT ABUSE WITH INTOXICATION, UNSPECIFIED |
| 249 | 10 | F15.14 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED MOOD DISORDER |
| 250 | 10 | F15.150 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 251 | 10 | F15.151 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 252 | 10 | F15.159 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 253 | 10 | F15.180 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED ANXIETY DISORDER |
| 254 | 10 | F15.181 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION |
| 255 | 10 | F15.182 | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SLEEP DISORDER |
| 256 | 10 | F15.188 | OTHER STIMULANT ABUSE WITH OTHER STIMULANT-INDUCED DISORDER |
| 257 | 10 | F15.19 | OTHER STIMULANT ABUSE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER |
| 258 | 10 | F15.20 | OTHER STIMULANT DEPENDENCE, UNCOMPLICATED |
| 259 | 10 | F15.220 | OTHER STIMULANT DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 260 | 10 | F15.221 | OTHER STIMULANT DEPENDENCE WITH INTOXICATION DELIRIUM |
| 261 | 10 | F15.222 | OTHER STIMULANT DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 262 | 10 | F15.229 | OTHER STIMULANT DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 263 | 10 | F15.23 | OTHER STIMULANT DEPENDENCE WITH WITHDRAWAL |
| 264 | 10 | F15.24 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED MOOD DISORDER |
| 265 | 10 | F15.250 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 266 | 10 | F15.251 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 267 | 10 | F15.259 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 268 | 10 | F15.280 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED ANXIETY DISORDER |
| 269 | 10 | F15.281 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION |
| 270 | 10 | F15.282 | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SLEEP DISORDER |
| 271 | 10 | F15.288 | OTHER STIMULANT DEPENDENCE WITH OTHER STIMULANT-INDUCED DISORDER |
| 272 | 10 | F15.29 | OTHER STIMULANT DEPENDENCE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER |
| 273 | 10 | F15.90 | OTHER STIMULANT USE, UNSPECIFIED, UNCOMPLICATED |
| 274 | 10 | F15.920 | OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 275 | 10 | F15.921 | OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION DELIRIUM |
| 276 | 10 | F15.922 | OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 277 | 10 | F15.929 | OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 278 | 10 | F15.93 | OTHER STIMULANT USE, UNSPECIFIED WITH WITHDRAWAL |
| 279 | 10 | F15.94 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER |
| 280 | 10 | F15.950 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 281 | 10 | F15.951 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 282 | 10 | F15.959 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 283 | 10 | F15.980 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER |
| 284 | 10 | F15.981 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION |
| 285 | 10 | F15.982 | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER |
| 286 | 10 | F15.988 | OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER |
| 287 | 10 | F15.99 | OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER |
| 288 | 10 | F1.610 | HALLUCINOGEN ABUSE, UNCOMPLICATED |
| 289 | 10 | F16.120 | HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 290 | 10 | F16.121 | HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM |
| 291 | 10 | F16.122 | HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 292 | 10 | F16.129 | HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED |
| 293 | 10 | F16.14 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER |
| 294 | 10 | F16.150 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 295 | 10 | F16.151 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 296 | 10 | F16.159 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 297 | 10 | F16.180 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER |
| 298 | 10 | F16.183 | HALLUCINOGEN ABUSE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS) |
| 299 | 10 | F16.188 | HALLUCINOGEN ABUSE WITH OTHER HALLUCINOGEN-INDUCED DISORDER |
| 300 | 10 | F16.19 | HALLUCINOGEN ABUSE WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER |
| 301 | 10 | F16.20 | HALLUCINOGEN DEPENDENCE, UNCOMPLICATED |
| 302 | 10 | F16.220 | HALLUCINOGEN DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 303 | 10 | F16.221 | HALLUCINOGEN DEPENDENCE WITH INTOXICATION WITH DELIRIUM |
| 304 | 10 | F16.229 | HALLUCINOGEN DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 305 | 10 | F16.24 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED MOOD DISORDER |
| 306 | 10 | F16.250 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 307 | 10 | F16.251 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 308 | 10 | F16.259 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 309 | 10 | F16.280 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER |
| 310 | 10 | F16.283 | HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS) |
| 311 | 10 | F16.288 | HALLUCINOGEN DEPENDENCE WITH OTHER HALLUCINOGEN-INDUCED DISORDER |
| 312 | 10 | F16.29 | HALLUCINOGEN DEPENDENCE WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER |
| 313 | 10 | F16.90 | HALLUCINOGEN USE, UNSPECIFIED, UNCOMPLICATED |
| 314 | 10 | F16.920 | HALLUCINOGEN USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 315 | 10 | F16.921 | HALLUCINOGEN USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM |
| 316 | 10 | F16.929 | HALLUCINOGEN USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 317 | 10 | F16.94 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED MOOD DISORDER |
| 318 | 10 | F16.950 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 319 | 10 | F16.951 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 320 | 10 | F16.959 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 321 | 10 | F16.980 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER |
| 322 | 10 | F16.983 | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS) |
| 323 | 10 | F16.988 | HALLUCINOGEN USE, UNSPECIFIED WITH OTHER HALLUCINOGEN-INDUCED DISORDER |
| 324 | 10 | F16.99 | HALLUCINOGEN USE, UNSPECIFIED WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER |
| 325 | 10 | F18.10 | INHALANT ABUSE, UNCOMPLICATED |
| 326 | 10 | F18.120 | INHALANT ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 327 | 10 | F18.121 | INHALANT ABUSE WITH INTOXICATION DELIRIUM |
| 328 | 10 | F18.129 | INHALANT ABUSE WITH INTOXICATION, UNSPECIFIED |
| 329 | 10 | F18.14 | INHALANT ABUSE WITH INHALANT-INDUCED MOOD DISORDER |
| 330 | 10 | F18.150 | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 331 | 10 | F18.151 | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 332 | 10 | F18.159 | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 333 | 10 | F18.17 | INHALANT ABUSE WITH INHALANT-INDUCED DEMENTIA |
| 334 | 10 | F18.180 | INHALANT ABUSE WITH INHALANT-INDUCED ANXIETY DISORDER |
| 335 | 10 | F18.188 | INHALANT ABUSE WITH OTHER INHALANT-INDUCED DISORDER |
| 336 | 10 | F18.19 | INHALANT ABUSE WITH UNSPECIFIED INHALANT-INDUCED DISORDER |
| 337 | 10 | F18.20 | INHALANT DEPENDENCE, UNCOMPLICATED |
| 338 | 10 | F18.220 | INHALANT DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 339 | 10 | F18.221 | INHALANT DEPENDENCE WITH INTOXICATION DELIRIUM |
| 340 | 10 | F18.229 | INHALANT DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 341 | 10 | F18.24 | INHALANT DEPENDENCE WITH INHALANT-INDUCED MOOD DISORDER |
| 342 | 10 | F18.250 | INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 343 | 10 | F18.251 | INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 344 | 10 | F18.259 | INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 345 | 10 | F18.27 | INHALANT DEPENDENCE WITH INHALANT-INDUCED DEMENTIA |
| 346 | 10 | F18.280 | INHALANT DEPENDENCE WITH INHALANT-INDUCED ANXIETY DISORDER |
| 347 | 10 | F18.288 | INHALANT DEPENDENCE WITH OTHER INHALANT-INDUCED DISORDER |
| 348 | 10 | F18.29 | INHALANT DEPENDENCE WITH UNSPECIFIED INHALANT-INDUCED DISORDER |
| 349 | 10 | F18.90 | INHALANT USE, UNSPECIFIED, UNCOMPLICATED |
| 350 | 10 | F18.920 | INHALANT USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 351 | 10 | F18.921 | INHALANT USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM |
| 352 | 10 | F18.929 | INHALANT USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 353 | 10 | F18.94 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED MOOD DISORDER |
| 354 | 10 | F18.950 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 355 | 10 | F18.951 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 356 | 10 | F18.959 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 357 | 10 | F18.97 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PERSISTING DEMENTIA |
| 358 | 10 | F18.980 | INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED ANXIETY DISORDER |
| 359 | 10 | F18.988 | INHALANT USE, UNSPECIFIED WITH OTHER INHALANT-INDUCED DISORDER |
| 360 | 10 | F18.99 | INHALANT USE, UNSPECIFIED WITH UNSPECIFIED INHALANT-INDUCED DISORDER |
| 361 | 10 | F19.10 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED |
| 362 | 10 | F19.120 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION, UNCOMPLICATED |
| 363 | 10 | F19.121 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION DELIRIUM |
| 364 | 10 | F19.122 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCES |
| 365 | 10 | F19.129 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION, UNSPECIFIED |
| 366 | 10 | F19.14 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER |
| 367 | 10 | F19.150 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 368 | 10 | F19.151 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 369 | 10 | F19.159 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 370 | 10 | F19.16 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER |
| 371 | 10 | F19.17 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA |
| 372 | 10 | F19.180 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER |
| 373 | 10 | F19.181 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION |
| 374 | 10 | F19.182 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER |
| 375 | 10 | F19.188 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER |
| 376 | 10 | F19.19 | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER |
| 377 | 10 | F19.20 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE, UNCOMPLICATED |
| 378 | 10 | F19.220 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED |
| 379 | 10 | F19.221 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION DELIRIUM |
| 380 | 10 | F19.222 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 381 | 10 | F19.229 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNSPECIFIED |
| 382 | 10 | F19.230 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED |
| 383 | 10 | F19.231 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL DELIRIUM |
| 384 | 10 | F19.232 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE |
| 385 | 10 | F19.239 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED |
| 386 | 10 | F19.24 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER |
| 387 | 10 | F19.250 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 388 | 10 | F19.251 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 389 | 10 | F19.259 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 390 | 10 | F19.26 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER |
| 391 | 10 | F19.27 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA |
| 392 | 10 | F19.280 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER |
| 393 | 10 | F1.9281 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION |
| 394 | 10 | F19.282 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER |
| 395 | 10 | F19.288 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER |
| 396 | 10 | F19.29 | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER |
| 397 | 10 | F19.90 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED, UNCOMPLICATED |
| 398 | 10 | F19.920 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED |
| 399 | 10 | F19.921 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM |
| 400 | 10 | F19.922 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE |
| 401 | 10 | F19.929 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED |
| 402 | 10 | F19.930 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL, UNCOMPLICATED |
| 403 | 10 | F19.931 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL DELIRIUM |
| 404 | 10 | F19.932 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE |
| 405 | 10 | F19.939 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL, UNSPECIFIED |
| 406 | 10 | F19.94 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER |
| 407 | 10 | F19.950 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| 408 | 10 | F19.951 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| 409 | 10 | F19.959 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED |
| 410 | 10 | F19.96 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER |
| 411 | 10 | F19.97 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA |
| 412 | 10 | F19.980 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER |
| 413 | 10 | F19.981 | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION |
| 1. These codes are adapted from list curated by the Mental Health Research Network available on GitHub.  2. To be included, the code appearing in a patient’s record must match the listed code exactly; codes with additional characters or digits are not valid matches. | | | |

| Table SUI. Suicide or self harm diagnoses.1 | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**2 | **ICD description** |
| 1 | 9 | E950.\* | Suicide and self-inflicted poisoning by solid or liquid substances |
| 2 | 9 | E951.\* | Suicide and self-inflicted poisoning by gases in domestic use |
| 3 | 9 | E952.\* | Suicide and self-inflicted poisoning by other gases and vapors |
| 4 | 9 | E953.\* | Suicide and self-inflicted injury by hanging strangulation and suffocation |
| 5 | 9 | E954.\* | Suicide and self-inflicted injury by submersion [drowning] |
| 6 | 9 | E955.\* | Suicide and self-inflicted injury by firearms air guns and explosives |
| 7 | 9 | E956.\* | Suicide and self-inflicted injury by cutting and piercing instrument |
| 8 | 9 | E957.\* | Suicide and self-inflicted injuries by jumping from high place |
| 9 | 9 | E958.\* | Suicide and self-inflicted injury by other and unspecified means |
| 10 | 10 | T14.91\* | Suicide attempt |
| 11 | 10 | T36.0X2\* | Poisoning by penicillins, intentional self-harm |
| 12 | 10 | T36.1X2\* | Poisn by cephalospor/oth beta-lactm antibiot, slf-hrm |
| 13 | 10 | T36.2X2\* | Poisoning by chloramphenicol group, self-harm |
| 14 | 10 | T36.3X2\* | Poisoning by macrolides, intentional self-harm |
| 15 | 10 | T36.4X2\* | Poisoning by tetracyclines, intentional self-harm |
| 16 | 10 | T36.5X2\* | Poisoning by aminoglycosides, intentional self-harm |
| 17 | 10 | T36.6X2\* | Poisoning by rifampicins, intentional self-harm |
| 18 | 10 | T36.7X2\* | Poisoning by antifungal antibiot, sys used, self-harm |
| 19 | 10 | T36.8X2\* | Poisoning by oth systemic antibiotics, self-harm |
| 20 | 10 | T36.92X\* | Poisoning by unsp systemic antibiotic, self-harm |
| 21 | 10 | T37.0X2\* | Poisoning by sulfonamides, intentional self-harm |
| 22 | 10 | T37.1X2\* | Poisoning by antimycobacterial drugs, self-harm |
| 23 | 10 | T37.2X2\* | Poisn by antimalari/drugs act on bld protzoa, slf-hrm |
| 24 | 10 | T37.3X2\* | Poisoning by oth antiprotozoal drugs, self-harm |
| 25 | 10 | T37.4X2\* | Poisoning by anthelminthics, intentional self-harm |
| 26 | 10 | T37.5X2\* | Poisoning by antiviral drugs, intentional self-harm |
| 27 | 10 | T37.8X2\* | Poisn by oth systemic anti-infect/parasit, self-harm |
| 28 | 10 | T37.92X\* | Poisn by unsp sys anti-infect and antiparastc, slf-hrm |
| 29 | 10 | T38.0X2\* | Poisoning by glucocort/synth analog, self-harm |
| 30 | 10 | T38.1X2\* | Poisoning by thyroid hormones and sub, self-harm |
| 31 | 10 | T38.2X2\* | Poisoning by antithyroid drugs, intentional self-harm |
| 32 | 10 | T38.3X2\* | Poisn by insulin and oral hypoglycemic drugs, slf-hrm |
| 33 | 10 | T38.4X2\* | Poisoning by oral contraceptives, self-harm |
| 34 | 10 | T38.5X2\* | Poisoning by oth estrogens and progestogens, self-harm |
| 35 | 10 | T38.6X2\* | Poisn by antigonadtr/antiestr/antiandrg, NEC, slf-hrm |
| 36 | 10 | T38.7X2\* | Poisn by androgens and anabolic congeners, self-harm |
| 37 | 10 | T38.802\* | Poisn by unsp hormones and synthetic sub, self-harm |
| 38 | 10 | T38.812\* | Poisoning by anterior pituitary hormones, self-harm |
| 39 | 10 | T38.892\* | Poisoning by oth hormones and synthetic sub, self-harm |
| 40 | 10 | T38.902\* | Poisoning by unsp hormone antagonists, self-harm |
| 41 | 10 | T38.992\* | Poisoning by oth hormone antagonists, self-harm |
| 42 | 10 | T39.012\* | Poisoning by aspirin, intentional self-harm |
| 43 | 10 | T39.092\* | Poisoning by salicylates, intentional self-harm |
| 44 | 10 | T39.1X2\* | Poisoning by 4-Aminophenol derivatives, self-harm |
| 45 | 10 | T39.2X2\* | Poisoning by pyrazolone derivatives, self-harm |
| 46 | 10 | T39.312\* | Poisoning by propionic acid derivatives, self-harm |
| 47 | 10 | T39.392\* | Poisn by oth nonsteroid anti-inflam drugs, self-harm |
| 48 | 10 | T39.4X2\* | Poisoning by antirheumatics, NEC, self-harm |
| 49 | 10 | T39.8X2\* | Poisn by oth nonopio analges/antipyret, NEC, self-harm |
| 50 | 10 | T39.92X\* | Poisn by unsp nonopi analgs/antipyr/antirheu, slf-hrm |
| 51 | 10 | T40.0X2\* | Poisoning by opium, intentional self-harm |
| 52 | 10 | T40.1X2\* | Poisoning by heroin, intentional self-harm |
| 53 | 10 | T40.2X2\* | Poisoning by oth opioids, intentional self-harm |
| 54 | 10 | T40.3X2\* | Poisoning by methadone, intentional self-harm |
| 55 | 10 | T40.4X2\* | Poisoning by oth synthetic narcotics, self-harm |
| 56 | 10 | T40.5X2\* | Poisoning by cocaine, intentional self-harm |
| 57 | 10 | T40.602\* | Poisoning by unsp narcotics, intentional self-harm |
| 58 | 10 | T40.692\* | Poisoning by oth narcotics, intentional self-harm |
| 59 | 10 | T40.7X2\* | Poisoning by cannabis (derivatives), self-harm |
| 60 | 10 | T40.8X2\* | Poisoning by lysergide, intentional self-harm |
| 61 | 10 | T40.902\* | Poisoning by unsp psychodysleptics, self-harm |
| 62 | 10 | T40.992\* | Poisoning by oth psychodysleptics, self-harm |
| 63 | 10 | T41.0X2\* | Poisoning by inhaled anesthetics, self-harm |
| 64 | 10 | T41.1X2\* | Poisoning by intravenous anesthetics, self-harm |
| 65 | 10 | T41.202\* | Poisoning by unsp general anesthetics, self-harm |
| 66 | 10 | T41.292\* | Poisoning by oth general anesthetics, self-harm |
| 67 | 10 | T41.3X2\* | Poisoning by local anesthetics, intentional self-harm |
| 68 | 10 | T41.42X\* | Poisoning by unsp anesthetic, intentional self-harm |
| 69 | 10 | T41.5X2\* | Poisoning by therapeutic gases, intentional self-harm |
| 70 | 10 | T42.0X2\* | Poisoning by hydantoin derivatives, self-harm |
| 71 | 10 | T42.1X2\* | Poisoning by iminostilbenes, intentional self-harm |
| 72 | 10 | T42.2X2\* | Poisn by succinimides and oxazolidinediones, self-harm |
| 73 | 10 | T42.3X2\* | Poisoning by barbiturates, intentional self-harm |
| 74 | 10 | T42.4X2\* | Poisoning by benzodiazepines, intentional self-harm |
| 75 | 10 | T42.5X2\* | Poisoning by mixed antiepileptics, self-harm |
| 76 | 10 | T42.6X2\* | Poisn by oth antieplptc and sed-hypntc drugs, slf-hrm |
| 77 | 10 | T42.72X\* | Poisn by unsp antieplptc and sed-hypntc drugs, slf-hrm |
| 78 | 10 | T42.8X2\* | Poisn by antiparkns drug/centr musc-tone depr, slf-hrm |
| 79 | 10 | T43.012\* | Poisoning by tricyclic antidepressants, self-harm |
| 80 | 10 | T43.022\* | Poisoning by tetracyclic antidepressants, self-harm |
| 81 | 10 | T43.1X2\* | Poisoning by MAO inhib antidepressants, self-harm |
| 82 | 10 | T43.202\* | Poisoning by unsp antidepressants, self-harm |
| 83 | 10 | T43.212\* | Poisn by slctv seroton/norepineph reup inhibtr,slf-hrm |
| 84 | 10 | T43.222\* | Poisn by slctv serotonin reuptake inhibtr, self-harm |
| 85 | 10 | T43.292\* | Poisoning by oth antidepressants, self-harm |
| 86 | 10 | T43.3X2\* | Poisn by phenothiaz antipsychot/neurolept, self-harm |
| 87 | 10 | T43.4X2\* | Poisn by butyrophen/thiothixen neuroleptc, self-harm |
| 88 | 10 | T43.502\* | Poisoning by unsp antipsychot/neurolept, self-harm |
| 89 | 10 | T43.592\* | Poisoning by oth antipsychot/neurolept, self-harm |
| 90 | 10 | T43.602\* | Poisoning by unsp psychostimulants, self-harm |
| 91 | 10 | T43.612\* | Poisoning by caffeine, intentional self-harm |
| 92 | 10 | T43.622\* | Poisoning by amphetamines, intentional self-harm |
| 93 | 10 | T43.632\* | Poisoning by methylphenidate, intentional self-harm |
| 94 | 10 | T43.692\* | Poisoning by oth psychostimulants, self-harm |
| 95 | 10 | T43.8X2\* | Poisoning by oth psychotropic drugs, self-harm |
| 96 | 10 | T43.92X\* | Poisoning by unsp psychotropic drug, self-harm |
| 97 | 10 | T44.0X2\* | Poisoning by anticholinesterase agents, self-harm |
| 98 | 10 | T44.1X2\* | Poisoning by oth parasympathomimetics, self-harm |
| 99 | 10 | T44.2X2\* | Poisoning by ganglionic blocking drugs, self-harm |
| 100 | 10 | T44.3X2\* | Poisn by oth parasympath and spasmolytics, self-harm |
| 101 | 10 | T44.4X2\* | Poisn by predom alpha-adrenocpt agonists, self-harm |
| 102 | 10 | T44.5X2\* | Poisoning by predom beta-adrenocpt agonists, self-harm |
| 103 | 10 | T44.6X2\* | Poisoning by alpha-adrenocpt antagonists, self-harm |
| 104 | 10 | T44.7X2\* | Poisoning by beta-adrenocpt antagonists, self-harm |
| 105 | 10 | T44.8X2\* | Poisn by centr-acting/adren-neurn-block agnt, slf-hrm |
| 106 | 10 | T44.902\* | Poisn by unsp drugs aff the autonm nrv sys, slf-hrm |
| 107 | 10 | T44.992\* | Poisn by oth drug aff the autonm nervous sys, slf-hrm |
| 108 | 10 | T45.0X2\* | Poisoning by antiallerg/antiemetic, self-harm |
| 109 | 10 | T45.1X2\* | Poisoning by antineopl and immunosup drugs, self-harm |
| 110 | 10 | T45.2X2\* | Poisoning by vitamins, intentional self-harm |
| 111 | 10 | T45.3X2\* | Poisoning by enzymes, intentional self-harm |
| 112 | 10 | T45.4X2\* | Poisoning by iron and its compounds, self-harm |
| 113 | 10 | T45.512\* | Poisoning by anticoagulants, intentional self-harm |
| 114 | 10 | T45.522\* | Poisoning by antithrombotic drugs, self-harm |
| 115 | 10 | T45.602\* | Poisoning by unsp fibrin-affct drugs, self-harm |
| 116 | 10 | T45.612\* | Poisoning by thrombolytic drug, intentional self-harm |
| 117 | 10 | T45.622\* | Poisoning by hemostatic drug, intentional self-harm |
| 118 | 10 | T45.692\* | Poisoning by oth fibrin-affct drugs, self-harm |
| 119 | 10 | T45.7X2\* | Poisn by anticoag antag, vit K and oth coag, slf-hrm |
| 120 | 10 | T45.8X2\* | Poisn by oth prim sys and hematolog agents, slf-hrm |
| 121 | 10 | T45.92X\* | Poisn by unsp prim sys and hematolog agent, slf-hrm |
| 122 | 10 | T46.0X2\* | Poisn by cardi-stim glycos/drug simlar act, self-harm |
| 123 | 10 | T46.1X2\* | Poisoning by calcium-channel blockers, self-harm |
| 124 | 10 | T46.2X2\* | Poisoning by oth antidysrhythmic drugs, self-harm |
| 125 | 10 | T46.3X2\* | Poisoning by coronary vasodilators, self-harm |
| 126 | 10 | T46.4X2\* | Poisn by angiotens-convert-enzyme inhibtr, self-harm |
| 127 | 10 | T46.5X2\* | Poisoning by oth antihypertensive drugs, self-harm |
| 128 | 10 | T46.6X2\* | Poisn by antihyperlip and antiarterio drugs, self-harm |
| 129 | 10 | T46.7X2\* | Poisoning by peripheral vasodilators, self-harm |
| 130 | 10 | T46.8X2\* | Poisn by antivaric drugs, inc scler agents, self-harm |
| 131 | 10 | T46.902\* | Poisn by unsp agents aff the cardiovasc sys, self-harm |
| 132 | 10 | T46.992\* | Poisn by oth agents aff the cardiovasc sys, self-harm |
| 133 | 10 | T47.0X2\* | Poisoning by histamine H2-receptor blockers, self-harm |
| 134 | 10 | T47.1X2\* | Poisn by oth antacids & anti-gstrc-sec drugs, slf-hrm |
| 135 | 10 | T47.2X2\* | Poisoning by stimulant laxatives, self-harm |
| 136 | 10 | T47.3X2\* | Poisoning by saline and osmotic laxatives, self-harm |
| 137 | 10 | T47.4X2\* | Poisoning by oth laxatives, intentional self-harm |
| 138 | 10 | T47.5X2\* | Poisoning by digestants, intentional self-harm |
| 139 | 10 | T47.6X2\* | Poisoning by antidiarrheal drugs, self-harm |
| 140 | 10 | T47.7X2\* | Poisoning by emetics, intentional self-harm |
| 141 | 10 | T47.8X2\* | Poisoning by oth agents aff GI sys, self-harm |
| 142 | 10 | T47.92X\* | Poisoning by unsp agents aff the GI sys, self-harm |
| 143 | 10 | T48.0X2\* | Poisoning by oxytocic drugs, intentional self-harm |
| 144 | 10 | T48.1X2\* | Poisoning by skeletal muscle relaxants, self-harm |
| 145 | 10 | T48.202\* | Poisoning by unsp drugs acting on muscles, self-harm |
| 146 | 10 | T48.292\* | Poisoning by oth drugs acting on muscles, self-harm |
| 147 | 10 | T48.3X2\* | Poisoning by antitussives, intentional self-harm |
| 148 | 10 | T48.4X2\* | Poisoning by expectorants, intentional self-harm |
| 149 | 10 | T48.5X2\* | Poisoning by oth anti-common-cold drugs, self-harm |
| 150 | 10 | T48.6X2\* | Poisoning by antiasthmatics, intentional self-harm |
| 151 | 10 | T48.902\* | Poisn by unsp agents prim act on the resp sys, slf-hrm |
| 152 | 10 | T48.992\* | Poisn by oth agents prim act on the resp sys, slf-hrm |
| 153 | 10 | T49.0X2\* | Poisn by local antifung/infect/inflamm drugs, slf-hrm |
| 154 | 10 | T49.1X2\* | Poisoning by antipruritics, intentional self-harm |
| 155 | 10 | T49.2X2\* | Poisoning by local astringents/detergents, self-harm |
| 156 | 10 | T49.3X2\* | Poisn by emollients, demulcents and protect, self-harm |
| 157 | 10 | T49.4X2\* | Poisn by keratolyt/keratplst/hair trmt drug, self-harm |
| 158 | 10 | T49.5X2\* | Poisoning by opth drugs and preparations, self-harm |
| 159 | 10 | T49.6X2\* | Poisoning by otorhino drugs and prep, self-harm |
| 160 | 10 | T49.7X2\* | Poisn by dental drugs, topically applied, self-harm |
| 161 | 10 | T49.8X2\* | Poisoning by oth topical agents, intentional self-harm |
| 162 | 10 | T49.92X\* | Poisoning by unsp topical agent, intentional self-harm |
| 163 | 10 | T50.0X2\* | Poisoning by mineralocorticoids and antag, self-harm |
| 164 | 10 | T50.1X2\* | Poisoning by loop diuretics, intentional self-harm |
| 165 | 10 | T50.2X2\* | Poisn by crbnc-anhydr inhibtr,benzo/oth diuretc,slf-hrm,init |
| 166 | 10 | T50.3X2\* | Poisn by electrolytic/caloric/wtr-bal agnt, self-harm |
| 167 | 10 | T50.4X2\* | Poisoning by drugs aff uric acid metab, self-harm |
| 168 | 10 | T50.5X2\* | Poisoning by appetite depressants, self-harm |
| 169 | 10 | T50.6X2\* | Poisoning by antidotes and chelating agents, self-harm |
| 170 | 10 | T50.7X2\* | Poisn by analeptics and opioid receptor antag, slf-hrm |
| 171 | 10 | T50.8X2\* | Poisoning by diagnostic agents, intentional self-harm |
| 172 | 10 | T50.902\* | Poisoning by unsp drug/meds/biol subst, self-harm |
| 173 | 10 | T50.992\* | Poisoning by oth drug/meds/biol subst, self-harm |
| 174 | 10 | T50.A12\* | Poisn by pertuss vaccn, inc combin w pertuss, slf-hrm |
| 175 | 10 | T50.A22\* | Poisn by mixed bact vaccines w/o a pertuss, self-harm |
| 176 | 10 | T50.A92\* | Poisoning by oth bacterial vaccines, self-harm |
| 177 | 10 | T50.B12\* | Poisoning by smallpox vaccines, intentional self-harm |
| 178 | 10 | T50.B92\* | Poisoning by oth viral vaccines, intentional self-harm |
| 179 | 10 | T50.Z12\* | Poisoning by immunoglobulin, intentional self-harm |
| 180 | 10 | T50.Z92\* | Poisoning by oth vaccines and biolg substnc, self-harm |
| 181 | 10 | T51.0X2\* | Toxic effect of ethanol, intentional self-harm |
| 182 | 10 | T51.1X2\* | Toxic effect of methanol, intentional self-harm |
| 183 | 10 | T51.2X2\* | Toxic effect of 2-Propanol, intentional self-harm |
| 184 | 10 | T51.3X2\* | Toxic effect of fusel oil, intentional self-harm |
| 185 | 10 | T51.8X2\* | Toxic effect of oth alcohols, intentional self-harm |
| 186 | 10 | T51.92X\* | Toxic effect of unsp alcohol, intentional self-harm |
| 187 | 10 | T52.0X2\* | Toxic effect of petroleum products, self-harm |
| 188 | 10 | T52.1X2\* | Toxic effect of benzene, intentional self-harm |
| 189 | 10 | T52.2X2\* | Toxic effect of homologues of benzene, self-harm |
| 190 | 10 | T52.3X2\* | Toxic effect of glycols, intentional self-harm |
| 191 | 10 | T52.4X2\* | Toxic effect of ketones, intentional self-harm |
| 192 | 10 | T52.8X2\* | Toxic effect of organic solvents, self-harm |
| 193 | 10 | T52.92X\* | Toxic effect of unsp organic solvent, self-harm |
| 194 | 10 | T53.0X2\* | Toxic effect of carbon tetrachloride, self-harm |
| 195 | 10 | T53.1X2\* | Toxic effect of chloroform, intentional self-harm |
| 196 | 10 | T53.2X2\* | Toxic effect of trichloroethylene, self-harm |
| 197 | 10 | T53.3X2\* | Toxic effect of tetrachloroethylene, self-harm |
| 198 | 10 | T53.4X2\* | Toxic effect of dichloromethane, intentional self-harm |
| 199 | 10 | T53.5X2\* | Toxic effect of chlorofluorocarbons, self-harm |
| 200 | 10 | T53.6X2\* | Tox eff of halgn deriv of aliphatic hydrocrb, slf-hrm |
| 201 | 10 | T53.7X2\* | Toxic eff of halgn deriv of aromatic hydrocrb, slf-hrm |
| 202 | 10 | T53.92X\* | Tox eff of unsp halgn deriv of aromat hydrocrb,slf-hrm |
| 203 | 10 | T54.0X2\* | Toxic effect of phenol and phenol homolog, self-harm |
| 204 | 10 | T54.1X2\* | Toxic effect of corrosive organic compounds, self-harm |
| 205 | 10 | T54.2X2\* | Tox eff of corrosv acids & acid-like substnc, slf-hrm |
| 206 | 10 | T54.3X2\* | Tox eff of corrosv alkalis & alk-like substnc, slf-hrm |
| 207 | 10 | T54.92X\* | Toxic effect of unsp corrosive substance, self-harm |
| 208 | 10 | T55.0X2\* | Toxic effect of soaps, intentional self-harm |
| 209 | 10 | T55.1X2\* | Toxic effect of detergents, intentional self-harm |
| 210 | 10 | T56.0X2\* | Toxic effect of lead and its compounds, self-harm |
| 211 | 10 | T56.1X2\* | Toxic effect of mercury and its compounds, self-harm |
| 212 | 10 | T56.2X2\* | Toxic effect of chromium and its compounds, self-harm |
| 213 | 10 | T56.3X2\* | Toxic effect of cadmium and its compounds, self-harm |
| 214 | 10 | T56.4X2\* | Toxic effect of copper and its compounds, self-harm |
| 215 | 10 | T56.5X2\* | Toxic effect of zinc and its compounds, self-harm |
| 216 | 10 | T56.6X2\* | Toxic effect of tin and its compounds, self-harm |
| 217 | 10 | T56.7X2\* | Toxic effect of beryllium and its compounds, self-harm |
| 218 | 10 | T56.812\* | Toxic effect of thallium, intentional self-harm |
| 219 | 10 | T56.892\* | Toxic effect of oth metals, intentional self-harm |
| 220 | 10 | T56.92X\* | Toxic effect of unsp metal, intentional self-harm |
| 221 | 10 | T57.0X2\* | Toxic effect of arsenic and its compounds, self-harm |
| 222 | 10 | T57.1X2\* | Toxic effect of phosphorus and its compnd, self-harm |
| 223 | 10 | T57.2X2\* | Toxic effect of manganese and its compounds, self-harm |
| 224 | 10 | T57.3X2\* | Toxic effect of hydrogen cyanide, self-harm |
| 225 | 10 | T57.8X2\* | Toxic effect of inorganic substances, self-harm |
| 226 | 10 | T57.92X\* | Toxic effect of unsp inorganic substance, self-harm |
| 227 | 10 | T58.02X\* | Toxic eff of carb monx from mtr veh exhaust, slf-hrm |
| 228 | 10 | T58.12X\* | Toxic effect of carb monx from utility gas, self-harm |
| 229 | 10 | T58.2X2\* | Tox eff of carb monx fr incmpl combst dmst fuel,slf-hrm,init |
| 230 | 10 | T58.8X2\* | Toxic effect of carb monx from oth source, self-harm |
| 231 | 10 | T58.92X\* | Toxic effect of carb monx from unsp source, self-harm |
| 232 | 10 | T59.0X2\* | Toxic effect of nitrogen oxides, intentional self-harm |
| 233 | 10 | T59.1X2\* | Toxic effect of sulfur dioxide, intentional self-harm |
| 234 | 10 | T59.2X2\* | Toxic effect of formaldehyde, intentional self-harm |
| 235 | 10 | T59.3X2\* | Toxic effect of lacrimogenic gas, self-harm |
| 236 | 10 | T59.4X2\* | Toxic effect of chlorine gas, intentional self-harm |
| 237 | 10 | T59.5X2\* | Tox eff of fluorine gas and hydrogen fluoride, slf-hrm |
| 238 | 10 | T59.6X2\* | Toxic effect of hydrogen sulfide, self-harm |
| 239 | 10 | T59.7X2\* | Toxic effect of carbon dioxide, intentional self-harm |
| 240 | 10 | T59.812\* | Toxic effect of smoke, intentional self-harm |
| 241 | 10 | T59.892\* | Toxic effect of gases, fumes and vapors, self-harm |
| 242 | 10 | T59.92X\* | Toxic effect of unsp gases, fumes and vapors, slf-hrm |
| 243 | 10 | T60.0X2\* | Toxic eff of organophos and carbamate insect, slf-hrm |
| 244 | 10 | T60.1X2\* | Toxic effect of halogenated insecticides, self-harm |
| 245 | 10 | T60.2X2\* | Toxic effect of insecticides, intentional self-harm |
| 246 | 10 | T60.3X2\* | Toxic effect of herbicides and fungicides, self-harm |
| 247 | 10 | T60.4X2\* | Toxic effect of rodenticides, intentional self-harm |
| 248 | 10 | T60.8X2\* | Toxic effect of oth pesticides, intentional self-harm |
| 249 | 10 | T60.92X\* | Toxic effect of unsp pesticide, intentional self-harm |
| 250 | 10 | T61.02X\* | Ciguatera fish poisoning, intentional self-harm |
| 251 | 10 | T61.12X\* | Scombroid fish poisoning, intentional self-harm |
| 252 | 10 | T61.772\* | Other fish poisoning, intentional self-harm |
| 253 | 10 | T61.782\* | Oth shellfish poisoning, intentional self-harm |
| 254 | 10 | T61.8X2\* | Toxic effect of oth seafood, intentional self-harm |
| 255 | 10 | T61.92X\* | Toxic effect of unsp seafood, intentional self-harm |
| 256 | 10 | T62.0X2\* | Toxic effect of ingested mushrooms, self-harm |
| 257 | 10 | T62.1X2\* | Toxic effect of ingested berries, self-harm |
| 258 | 10 | T62.2X2\* | Toxic effect of ingested (parts of) plant(s), slf-hrm |
| 259 | 10 | T62.8X2\* | Toxic effect of noxious substnc eaten as food, slf-hrm |
| 260 | 10 | T62.92X\* | Toxic eff of unsp noxious sub eaten as food, slf-hrm |
| 261 | 10 | T63.002\* | Toxic effect of unsp snake venom, self-harm |
| 262 | 10 | T63.012\* | Toxic effect of rattlesnake venom, self-harm |
| 263 | 10 | X71\* | Intentional self-harm by drowning and submersion |
| 264 | 10 | X72\* | Intentional self-harm by handgun discharge |
| 265 | 10 | X73\* | Intentional self-harm by rifle, shotgun and larger firearm discharge |
| 266 | 10 | X74\* | Intentional self-harm by other and unspecified firearm and gun discharge |
| 267 | 10 | X75\* | Intentional self-harm by explosive material |
| 268 | 10 | X76\* | Intentional self-harm by smoke, fire and flames |
| 269 | 10 | X77\* | Intentional self-harm by steam, hot vapors and hot objects |
| 270 | 10 | X78\* | Intentional self-harm by sharp object |
| 271 | 10 | X79\* | Intentional self-harm by blunt object |
| 272 | 10 | X80\* | Intentional self-harm by jumping from a high place |
| 273 | 10 | X81\* | Intentional self-harm by jumping or lying in front of moving object |
| 274 | 10 | X82\* | Intentional self-harm by crashing of motor vehicle |
| 275 | 10 | X83\* | Intentional self-harm by other specified means |
| 1. These codes are adapted from list curated by the Mental Health Research Network available on GitHub.  2. Presence of an asterisk in a code indicates any code beginning with the characters to the left of the asterisk qualifies. Codes without an asterisk must match the listed code exactly. | | | |

| Table TOB. Tobacco use disorder and realated diagnosis codes. | | | |
| --- | --- | --- | --- |
| **Row** | **ICD era** | **ICD code**1 | **ICD description** |
| 1 | 9 | 305.1 | Tobacco use disorder |
| 2 | 10 | F17.2\* | Nicotine dependence |
| 3 | 10 | T65.2\* | Toxic effect of tobacco, nicotine, and cigarettes |
| 4 | 10 | Z71.6\* | Tobacco abuse counseling |
| 5 | 10 | Z72.0\* | Tobacco use |
| 6 | 10 | Z87.891 | Personal history of nicotine dependence |
| 1. Presence of an asterisk in a code indicates any code beginning with the characters to the left of the asterisk qualifies. Codes without an asterisk must match the listed code exactly. | | | |

| Table APM. Antipsychotic medication names.1 | | | |
| --- | --- | --- | --- |
| Row | Generation2 | Generic Name | Trade Name |
| 1 | First | CHLORPROMAZINE | THORAZINE |
| 2 | First | CHLORPROTHIXENE | TARACTEN |
| 3 | First | FLUPENTHIXOL | FLUANXOL |
| 4 | First | FLUPHENAZINE | PROLIXIN |
| 5 | First | HALOPERIDOL | HALDOL |
| 6 | First | LOXAPINE | LOXITANE |
| 7 | First | MESORIDAZINE | SERENTIL |
| 8 | First | MOLINDONE | MOBAN |
| 9 | First | THIOTHIXENE | NAVANE |
| 10 | First | PERPHENAZINE | TRILAFON |
| 11 | First | PIMOZIDE | ORAP |
| 12 | First | PROCHLORPERAZINE | COMPAZINE |
| 13 | First | PROMAZINE | SPARINE |
| 14 | First | THIORIDAZINE | MELLARIL |
| 15 | First | THIOTHIXENE | NAVANE |
| 16 | First | TRIFLUOPERAZINE | STELAZINE |
| 17 | Second | ARIPIPRAZOLE | ABILIFY |
| 18 | Second | ASENAPINE | SAPHRIS |
| 19 | Second | CLOZAPINE | CLOZARIL |
| 20 | Second | ILOPERIDONE | FANAPT |
| 21 | Second | OLANZAPINE | ZYPREXA |
| 22 | Second | PALIPERIDONE | INVEGA |
| 23 | Second | QUETIAPINE | SEROQUEL |
| 24 | Second | RISPERIDONE | RISPERDAL |
| 25 | Second | ZIPRASIDONE | GEODON |
| 26 | Second | LURASIDONE | LATUDA |
| 27 | Second | BREXPIPRAZOLE | REXULTI |
| 28 | Second | PIMAVANSERIN | NUPLAZID |
| 1. Adapted from medication lists created for the Mental Health Research Network (MHRN) available on GitHub (https://github.com/MHResearchNetwork/MHRN-Central). | | | |
| 2. First-generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Second-generation antipsychotics, known as atypical antipsychotics, were developed more recently but the first drug in this category, clozapine, was released in Europe in the 1970s. | | | |

References

1. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, Gill JM, Roberts B, Gallacher J, Mackay D, Hotopf M, Deary I, Craddock N, Pell JP. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. PloS one. 2013;8:e75362. PMCID: PMC3839907.

2. McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, Li R, Masys DR, Ritchie MD, Roden DM, Struewing JP, Wolf WA. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011;4:13. Epub 2011/01/29. PMCID: 3038887.

3. Ingram WM, Baker AM, Brown JP, Goes FS, Zandi PP, Larson S. Defining Depression Cohorts Using the EHR: Multiple Phenotypes Based on ICD-9 Codes and Medication Orders. bioRxiv. 2017.

4. Castro VM, Minnier J, Murphy SN, Kohane I, Churchill SE, Gainer V, Cai T, Hoffnagle AG, Dai Y, Block S, Weill SR, Nadal-Vicens M, Pollastri AR, Rosenquist JN, Goryachev S, Ongur D, Sklar P, Perlis RH, Smoller JW, International Cohort Collection for Bipolar Disorder C. Validation of electronic health record phenotyping of bipolar disorder cases and controls. Am J Psychiatry. 2015;172:363-72. PMCID: PMC4441333.

5. Gibbons LE, Feldman BJ, Crane HM, Mugavero M, Willig JH, Patrick D, Schumacher J, Saag M, Kitahata MM, Crane PK. Migrating from a legacy fixed-format measure to CAT administration: calibrating the PHQ-9 to the PROMIS depression measures. Qual Life Res. 2011;20:1349-57. PMCID: PMC3175024.

6. McDonald WM, Weiner RD, Fochtmann LJ, McCall WV. The FDA and ECT. The journal of ECT. 2016;32:75-7. PMCID: PMC5137581.